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ROBERT GORDON UNDERLY. The Response of Pericytes to Microvascular Ischemia.
(Under the direction of Andy Shih)
ABSTRACT

The goal of this research is to investigate the role of pericytes during ischemia,
and more specifically, to investigate their cell-specific proteolytic contributions that lead
to the degeneration of the blood-brain barrier (BBB). BBB degeneration represents a
pathological hallmark of ischemic stroke and is a major factor in limiting the window for
pharmacological treatments by increasing the likelihood for hemorrhagic transformation.
By understanding cell-specific proteolytic contributions to BBB degeneration during
ischemia, novel biomarkers to predict the severity of the injury as well as new targets to
reduce the extent of damage from stroke could be discovered.
Pericytes are a cell intricately linked with the microvasculature and are necessary
for the development and maintenance of the blood-brain barrier (BBB). While it is known
that genetic ablation of pericytes leads to increased cerebrovascular leakage and buildup
of neurotoxic molecules within the brain, the consequence of pericyte pathology in vivo
remains poorly understood. In our experiments we used in vivo two-photon imaging and
photothrombotic occlusions within the capillary bed to explore pericyte responses to
ischemia. We have also developed a novel application of a quenched (FITC) gelatin
probe (FITC-Gelatin), which rapidly increases several hundred-fold in fluorescence upon
gelatinolytic cleavage performed by matrix metalloproteinases (MMP). This probe allows
for in vivo two-photon imaging of MMP 2/9 activity with resolution at a cellular level.
We also implement numerous pharmacological agents in order to determine the
biochemical contributions to pericyte pathology during ischemia.
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We find that pericytes respond to ischemia with robust, locally active, MMP 9
which produces BBB degeneration at the location of pericyte somata. We have also found
that the MMP activity occurs within tens of minutes following the induction of ischemia
within the capillary bed and the cessation of blood flow is necessary for leakage to occur.
In addition we have found that the initial activation of MMP 9 can be blocked through the
inhibition of nitric oxide production (via L-NIL), and that this blockage occurs in a
pericyte specific manner. From this we conclude that pericytes are responsible for rapid
BBB degeneration during ischemia mediated through a post-translational activation of
MMP 9 by NO
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Chapter 1: General Introduction
1.1. The Blood-Brain Barrier
The blood-brain barrier (BBB) is composed of numerous cells and junctional connections
that form a tightly regulated barrier between molecules of the blood and the central nervous
system (CNS) (Begley, D. J. & Brightman, M. W., 2003; Zhao, Z. et al., 2015). These
components work in synchrony to maintain homeostatic balance within the CNS by allowing for
the transport of metabolites and other molecules necessary for cellular function across the barrier
(Wolburg, H. & Lippoldt, A., 2002). This regulatory function of the BBB is consistently present
from the pial surface arteries, down into the capillary bed, and across the venules and veins. The
regulation of this expansive network is mandatory for the stability of neuronal function, and
therefore, the survival of the organism (Abbott, N. J. et al., 2006).
The core cellular element of the BBB are endothelial cells. Endothelial cells of the CNS
have continuous junctions connecting each endothelial cell to the next as well as junctional
connections allowing for the flow of communication between cells (Aird, W. C., 2007;
Obermeier, B. et al., 2013). These junctional connections differentiate the endothelial cells of the
CNS from other tissue in that they provide continuous protection within the CNS (lack of
fenestration) (Bauer, H. et al., 1993). These junctional connections include tight junctions and gap
junctions. Continuous signaling between each endothelial cell and other cellular components of
the BBB is a function of gap junctional connections. Tight junctions, on the other hand, provide a
means of controlling the entry of blood-borne molecules from into the brain (Abbott, N. J. et al.,
2006).
Another important feature of the blood-brain barrier is the extracellular matrix (ECM).
The ECM is composed of structural proteins (collagen and elastin), adhesion proteins (fibronectin
and laminin), and protein complexes (proteoglycans) as well as signaling protein structures
(dystroglycan and integrins) which are involved in functional communication between cells of the
BBB and the ECM (Figure 1) (Yurchenco, P. D. & Schittny, J. C., 1990). Dystroglycan is
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contained mainly within perivascular cells and endothelial cells while integrins are present across
the spectrum of cells composing the BBB (Willis, C. L. et al., 2004). Integrins form a complex
network that allows for rapid modifications to cellular signaling within the changing
microenvironment of the BBB (Milner, R. & Campbell, I. L., 2002; Wang, J. & Milner, R.,
2006). The degradation of ECM proteins produces ligands that bind to a vast array of receptors
which allows for the modification of cellular coverage, plasticity and transport (Cambier, S. et al.,
2005; Huntley, G. W., 2012). As a result, subtle changes in these proteins can have a dramatic
influence during a variety of pathological or modulatory states within the CNS.

Figure 1. Composition and representative proteins of the extracellular matrix

1.1.1 Junctional components of the BBB
The selective permeability of the BBB is only possible with the appropriate regulation of
junctional proteins (Wolburg, H. & Lippoldt, A., 2002). One of the main factors contributing to
the integrity of the BBB are the junctional proteins that form cell-cell contacts between the cells
of the BBB (Wildenberg, G. A. et al., 2006). Junctional proteins also exist within the BBB to
allow for the production of membrane-cellular scaffolds (Nelson, W. J. & Nusse, R., 2004). The
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major groups of junctions are tight junctions, adherens junctions, and gap junctions with a variety
of other proteins comprising the cytoskeleton (actin) and allowing for the maintenance of BBB
integrity (junctional adhesion molecule, JAM, proteins) (Figure 2) (Wolburg, H. & Lippoldt, A.,
2002).
Tight junctions are composed of three main families of proteins; occludins, claudins, and
membrane-associated guanylate kinases (in this case the sub-family Zonula occludens) (Huber, J.
D. et al., 2001). Each of these proteins have a variety of isoforms that are expressed differentially
along the BBB limiting the size of molecules that can cross the BBB (claudin-5) (Morita, K.,
Sasaki, H., et al., 1999), the tightness of the BBB (claudin-1) (Furuse, M. et al., 1998), the
stability of cellular contacts (ZO 1-3) (Balda, M. S. & Anderson, J. M., 1993), and the integrity of
cell-cell tightness (occludin) (Furuse, M. et al., 1993). Stereotypic BBB properties are typically
associated with expression of the claudins (Morita, K., Furuse, M., et al., 1999) while occludins
are not required for normal TJ formation (Saitou, M. et al., 2000). Occludins, however, seem to
have the responsibility of maintaining the adhesion between cell-cell contacts (Balda, M. S. et al.,
2000). Zonula occludens on the other hand, are integral in the anchoring of membrane-cellular
contacts and therefore the stability of cytoskeletal scaffolds (Furuse, M. et al., 1994; Itoh, M. et
al., 1999).
Adherens junctions are predominately composed of cadherins and platelet endothelial cell
adhesion molecule (PECAM) (Schulze, C. & Firth, J. A., 1993). Adherens junctions provide a
link between cellular contacts as well as providing a means for modulating receptor signaling in
conjunction with integrins (Dejana, E., 1996; Huang, R.-L. et al., 2011). An important feature of
adherens junction proteins are the modulation of cytoskeleton proliferation by limiting the
activation of RhoA and the initiation of actin polymerization (Liu, F. et al., 2001). Modifications
to this pathway also allow for the activation of Rac which can cause the internalization of
cadherins and allow for cell mobilization and proliferation (Cavallaro, U. & Dejana, E., 2011).
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Maintaining the synchrony between these processes, in conjunction with integrin signaling,
promotes angiogenesis and normal vascular sprouting.
Gap junctions are connections that occur between cells in order to orchestrate and
synchronize the propagation of signaling between the cellular components of the BBB
(Nagasawa, K. et al., 2006). Ensembles of astrocytes, for example, have been shown to produce
modifications in vascular diameter through the propagation of Ca2+ to blood vessels in a
glutamate dependent manner (Zonta, M. et al., 2003). It should also be mentioned that although
intracellular calcium increases are a functional mechanism of astrocytes, a variety of receptors,
ion channels and metabolites have been hypothesized to be involved in the neurovascular
coupling without elevated internal calcium stores as previously mentioned (Mishra, A. et al.,
2016; Otsu, Y. et al., 2015). Early gap junctions between mural cells and endothelial cells, via
connexin 43, also play an important role in the differentiation of mural cells (Hirschi, K. K. et al.,
2003). Gap junctions may also play an important role in the regulation of tight junction proteins,
and as a result, allow for continued maintenance of the BBB (Nagasawa, K. et al., 2006).

Figure 2. Junctional components of the blood brain barrier.
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1.1.2 Cellular components of the BBB
Endothelial cells, pericytes, and astrocytes represent the major cells that constitute the
BBB. Endothelial cells and pericytes form the first cellular layer of the BBB between
interluminal space and the basement membrane. Residing directly outside of the basement
membrane are astrocytic endfeet which ensheath the abluminal surface of the blood vessels.
These cells provide an interface for communication between neurons and blood vessels, clear and
recycle neurotransmitters, provide a means of nutrient transport, and maintain vascular stability
through a variety of signaling cascades (Neuwelt, E. A. et al., 2011; Obermeier, B. et al., 2013).
Endothelial cells are the core cellular component of blood vessels, and as a consequence,
the core elemental of the BBB (Figure 3). Endothelial cells are integrated into sprouting vascular
branches through vascular endothelial growth factor (VEGF) (Shalaby, F. et al., 1995). The
genetic removal of this signaling molecule is embryonically lethal and prevents the initiation of
vascular formation (Carmeliet, P. et al., 1996). Although the initiation of endothelial cell
localization and new cell integration is mediated through VEGF signaling (Raab, S. et al., 2004),
a variety of vascular proteins are responsible for endothelial stability (ANG1) (Iurlaro, M. et al.,
2003; Sato, T. N. et al., 1995), cellular recruitment (MAPK pathway and Tie2 signaling)
(Rousseau, S. et al., 1997; Wakui, S. et al., 2006), vascular cell proliferation (VEGFR-2 via RASRAF-MEK) (Ferrara, N. et al., 1996; Witmer, A. N. et al., 2004) and endothelial cell survival
(PI3K-AKT) (Olsson, A.-K. et al., 2006). A variety of other cellular signaling cascades in
endothelial cells are responsible for driving the recruitment of other cellular components to the
BBB (Pdgf-b) (Daneman, R. et al., 2010a), adhesion of these cells (Tgf-β) (Dohgu, S. et al.,
2005), and production of BBB –specific genes (Wnt) important for the integration of glucose
transporters (Daneman, R. et al., 2009).
Endothelial cells represent an important locus for the transport of a variety of proteins,
metabolites, amino acids, fatty acids, nucleotides, and ions throughout the CNS (Roberts, L. et al.,
2008). These transporters can function in a unidirectional or bidirectional manner and through
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passive or receptor-mediated transport (Lin, L. et al., 2015). The transport of molecules can also
occur in a paracellular or transcellular fashion depending on the mode of transport (passive vs
receptor mediated) as well as the molecule being transported (Pardridge, W. M. & Oldendorf, W.
H., 1977). An example would be the transport of glutamate vs glucose. Glutamate can be
transported out of the brain against its concentration gradient (through excitatory amino acid
transporters, EAAT) while glucose (via GLUT1) is transported bidirectionally down its
concentration gradient (Simpson, I. A. et al., 1999; Smith, Q. R., 2000). These transporters are
integral in the maintenance of homeostatic balance within the CNS by shuttling out waste
products (misfolded proteins, excess amino acids and metabolite byproducts) and allowing for the
movement of nucleotides, nutrients, and an ions to maintain neuronal cell signaling and BBB
stability (Abbott, N. J., 2004; Abbott, N. J. et al., 2006). Although endothelial cells represent the
first major cell of the BBB, and an important cellular level of molecular regulation, a variety of
other cells are required to promote the selectively permeable nature of the BBB; one of these cells
are astrocytes.
Astrocytic endfeet are an important mediator of junctional integrity (Dehouck, M. P. et
al., 1990), localization of metabolite transporters (McAllister, M. S. et al., 2001), and the
promotion of cell-cell interactions of the BBB through the release of regulatory factors (Tgf-β
and Ang1/2, among numerous others) (Gaengel, K. et al., 2009; Lee, S.-W. et al., 2003).
Astrocytes function predominately through elevated levels of calcium within the cell, and through
the polarization of their endfeet. The polarization of astrocytic endfeet involves the localization of
aquaporin 4 to the perivascular connection of the endfeet (Satz, J. S. et al., 2010). This is formed
through a membrane complex composed of Argin and AQP4 along with α-syntrophin and may be
regulated by pericytes (Gundersen, G. A. et al., 2014). The result of this localization is the
appropriate transport of aqueous substances as well as the proper localization of metabolic
transporters (Haj-Yasein, N. N. et al., 2011; McAllister, M. S. et al., 2001). This localization
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allows astrocytes to mediate the passage of glucose from perivascular space to be used by
neurons for functional signaling (Iliff, J. J. et al., 2012; Pellerin, L. & Magistretti, P. J., 1994).
Astrocytic communication with the endothelium and perivascular cells also mediates
tight junction integrity and the rapid modification of extracellular matrix proteins (Alvarez, J. I. et
al., 2011; Simard, M. et al., 2003). They are also responsible for the initial production of the
ligand Angiopoietin1 (Ang1), which through the TIE2 receptor, produces ERK, PAK and AKT
allowing for the proliferation (ERK and PAK) (Fukuhara, S. et al., 2008), survival (AKT and
downstream effectors) (Saharinen, P. et al., 2008), and the homeostatic balance of vascular
constriction/dilation (Tie2  AKT  eNOS  NO) (Figure 3) (Duda, D. G. et al., 2004; Fulton,
D. et al., 1999). Astrocytic signaling with the endothelial also leads to the transcription of
proteolytic enzymes that promote loosening of tight junctions to allow for paracellular transport
(Abbott, N. J., 2002; Arai, K. et al., 2003; Schwaninger, M. et al., 1999).

Figure 3. Cellular components of the blood brain barrier with various signaling components.
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Pericytes are another integral cellular component of the blood-brain barrier. Pericytes are
spread in a heterogeneous manner across the entire spectrum of blood vessels, and are intimately
connected with the endothelium (Armulik, Annika et al., 2010). Pericytes are distinguished by
their ovoid cell bodies that reside between the basement membrane and the abluminal surface of
the endothelium (Grant, R. I. et al., 2017; Hartmann, David A et al., 2015). They seem to share
functional peg and socket connections with the endothelium, mediated through connexins and Ncadherin (Armulik, A. et al., 2011; Hirschi, K. K. et al., 2003; Sweeney, M. D. et al., 2016). With
the genetic deletion of pericytes, and the confirmation of their loss, it has been possible to
distinguish specific signaling pathways and a functional role for these cells (Heuchel, R. et al.,
1999; Lindahl, P., 1997).
Platelet derived growth factor β (Pdgf β) signaling, through its respective receptor, is the
signaling step in the pericyte life-cycle that promotes their migration to and proliferation (and
therefore coverage) along the BBB (Daneman, R. et al., 2010a; Hellström, M. et al., 1999;
Virgintino, D. et al., 2007). Genetic ablation of Pdgfr β leads to BBB leakage and is
embryonically lethal (Bjarnegård, M. et al., 2004; Winkler, E. A. et al., 2010). In animals with
reduce pericyte number, through a partial knockdown of Pdgfr β, animals experience increases in
a variety of pathological processes related to dysregulation of the BBB including abnormal
folding of the lumen, vascular leakage, and abnormal junctions (Hellström, M. et al., 1999).
Transforming growth factor β (Tgf β) is the signaling step by which the
integration/adhesion of pericytes into the BBB occurs. Both pericytes and endothelial cells have
been shown to secrete Tgf β, with the result being the differentiation of mural cells (either smooth
muscle cells or pericytes) and the adhesion of pericytes to the endothelium (Hirschi, K. K. et al.,
2003; Sweeney, M. D. et al., 2016). When this mechanism is modified through genetic
knockouts, most deficits are seen at the level of the endothelium. However, it is hard to
distinguish the relative contributions of mural cells to the resulting hemorrhagic outcomes of the
knockout.
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Finally, pericytes are an important regulator of vascular stability through the production
of Angiopoietin1 (von Tell, Desiree et al., 2006). The reciprocal stability of pericytes and
endothelial cells within the BBB seems to be maintained through the secretion of Ang1 by
pericytes and the binding of this ligand to Tie2 receptors on endothelial cells (Wakui, S. et al.,
2006). This signaling mechanism has been shown to be required for the propagation of vascular
sprouts and their respective coverage by pericytes (Obermeier, B. et al., 2013). When Ang1 is
overproduced blood vessel expansion occurs and the resulting expansion of the vascular network
leads to an intact BBB (Suri, C. et al., 1998). However, upon removal of pericyte-derived Ang1,
angiogenesis is brought to a halt and animals with this genetic mutation die very early (Suri, C. et
al., 1996). These result suggest that the Ang1/Tie2 signaling loop between pericytes and
endothelial cells is required for normal BBB production.

1.2. The Mural Cell Continuum
Rouget cells were first described in 1873 (Rouget, C., 1873) as contractile ovoid cells
within perivascular space longitudinally placed along the capillaries with extensive branched
processes. In 1902 Mayer (Mayer, S., 1902) found these same cells in the intestine and described
them as “much-branched muscle cells” due to the slow transition in morphology from the smooth
muscle cells found on larger vessels. They were later given the term “pericyte” by Zimmermann
(Zimmermann, K. W., 1923) who went one step further to describe subtypes of pericytes based
on location and morphology along the vascular tree and to differentiate them from smooth muscle
cells. Pericytes residing along the capillaries were given the distinction of being “spider-like”
while Zimmermann also noted that there seemed to be a transition from arteriole smooth muscle
cells into a type of pericyte that ensheathed vessels transitioning into the capillaries. Zimmermann
and Gurwitsch also noted these cells were found on the transition from capillaries into venules.
From the late 1860’s into the late 1920’s the origin, function, and name of these cells was the
focus of much attention and debate (reviewed by Bensley & Vimtrup, 1928).
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Figure 4. The mural cell continuum. a) Mural cells along a penetrating arteriole and
connecting branches. b) FITC-labeled endothelium showing the vascular network. c)
α-SMA labeled portions of the vascular tree. d) Overlay of mural cells and α-SMA
representing the shift in mural cell types. Modified from (Grant, R. I. et al., 2017)

Currently the general morphology and heterogeneity in the subtypes of central nervous
system mural cells has been well reported (Fernandez-Klett, F. & Priller, J., 2015; Grant, R. I. et
al., 2017; Hartmann, David A et al., 2015). A clear morphological distinction between pericytes
residing on pre-capillary arterioles, within the capillary bed, and on post-capillary venules exists.
These cells each have the distinct ovoid cell body of a pericyte with major variations in their
processes ramification and length as well as differences in the presence of contractile proteins (αsmooth muscle actin) (Grant, R. I. et al., 2017) (Figure 4). Little evidence demonstrating
variations in function differences between the cellular subtypes exists, but the lack of continuity
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in naming has led to some debate about the contractile roles of pericytes (Hall, C. N. et al., 2014;
Hill, R. A. et al., 2015). In the latter paper (by Hill et al), cells exhibiting the morphological
features of various subtypes of pericytes are described as vascular smooth muscle cells based on
cellular ensheathment of the vessel that they resides on. Numerous other papers however, have
pointed to these cells as distinct subtypes of pericytes that differ from smooth muscle cells.
Although heterogeneity in pericyte populations has been well demonstrated from the previous
studies there is little evidence differentiating protein expression between pericytes and other
mural cells, as well as between pericyte subtypes, with the exception of α-smooth muscle actin
(Grant, R. I. et al., 2017; Vanlandewijck, M. et al., 2018). Because of this, angioarchitecture has
become important in mural cell identification.
The terminology in describing the difference between blood vessels is an important tool
in the identification of cells along the mural cell continuum. To begin, blood vessels of the pial
surface are referred to simply as arteries, and represent the “beginning” of the vascular tree. As
these vessels begin to penetrate (descend) they are referred to as penetrating arterioles or 0th order
branches. These branches contain vascular smooth muscle cells that are α-SMA positive. As the
vessel penetrates and branches, each distinct branch along the penetrating arteriole becomes a 1st
order branch. The 1st order branch marks a critical point at which the vessel becomes referred to
as a pre-capillary arteriole. The subsequent bifurcations of a first order branch then become 2nd
order branches, and this trend continues for the rest of the capillary bed until the vessels begin to
ascend into post-capillary venules. Each subsequent bifurcation from 1st order branches and
beyond, regardless of branch order, is referred to as a precapillary arteriole until the termination
point of α-SMA. Prior to this point of termination cells having an ovoid cell body with processes
surrounding their associated vessel are referred to as ensheathing pericytes. After the terminus of
α-SMA, the vessels are then referred to as capillaries which contain the stereotypic capillary
pericyte with thin processes that do not fully cover the capillary lumen.
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Although little is known about the functional distinction between subpopulations of
pericytes, the functional significance of pericytes within the neurovascular unit (NVU), as well as
during the development of the NVU, has begun to unfold. Through the use of platelet-derived
growth factor receptor β (PDGFRβ) knockouts, CNS pericytes have been shown to play an
integral role in forming the blood-brain barrier (BBB) (Armulik, A. et al., 2005; Wakui, S. et al.,
2006), maintaining the integrity of the BBB (Armulik, Annika et al., 2010; Daneman, R. et al.,
2010a; von Tell, Desiree et al., 2006), and facilitating normal function of the NVU (Bell, R. D. et
al., 2010). As a result of this evidence, exploration of the response of pericytes to pathological
conditions, specifically ischemia, in vivo has begun to progress.

1.3. Stroke
Stroke is the leading cause of severe
disability in the United States and the total financial
burden is approximated at around thirty four billion
dollars (Control, C. f. D. & Prevention, 2012; Xu, J.
et al., 2016). Recently, the number of deaths from
stroke has declined, but the financial burden and
prevalence of disability has increased. Methods for
stroke intervention have also stagnated making
efforts to explore new interventions even more
important. By advancing our understanding of the
mechanisms underlying stroke progression novel
therapeutic targets can be defined.
Stroke is the consequence of the permanent

Figure 5. Ischemic and hemorrhagic
strokes with representative vascular
and cortical pathologies. (Images
modified from HealthLinkBC.ca).

or transient interruption of blood flow resulting in
the lack of nutrient and oxygen supply to brain tissue. The cessation of blood flow can occur
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through occlusions of the vasculature, a breakage in a blood vessel (hemorrhage), or the lack of
blood supply from the heart (heart disease/failure) (Figure 5). The outcome of each is a region of
cerebral damage, but the progression and size of the injury, as well as the resulting functional
deficits, differ between each type.

1.3.1. Hemorrhagic stroke
Of all strokes approximately 13% are hemorrhagic (Mozaffarian, D. et al., 2016). This
type of stroke can occur as a subarachnoid hemorrhage (SAH) or an intracerebral hemorrhage
(ICH), and is defined by the rupture of blood vessels with bleeding into peripheral tissue.
Hemorrhagic strokes have the highest mortality rate of all strokes with between 35 – 52% of
strokes leading to death (Testai, F. D. & Aiyagari, V., 2008). Hemorrhagic transformation of an
ischemic region of cerebral vasculature is most commonly caused by chronic hypertension. The
malformation of cerebral vessels from prolonged hypertension accounts for around 60% of
hemorrhagic strokes. These malformed vessels are the result of maladaptive proliferation of
smooth muscle cells. The result of the loss of these smooth muscle cells are decreases in vascular
tone and poor perfusion (Sutherland, G. R. & Auer, R. N., 2006).
Hemorrhagic stroke is difficult to treat as the rupture of vasculature makes thrombolytic
treatments unusable in most circumstances. When thrombolytic agents are used, with a resulting
hemorrhage, the mortality rate soars to 60% (Group, N. t.-P. S. S., 1997). If warning signs in
patients are seen, anticoagulants can be used with relative effectiveness. The same is true for
antiplatelet medications such as aspirin. However, the underlying issue with the treatment of
hemorrhagic stroke is the containment of the event after it has occurred. With improvements in
the ability to prevent exacerbation of the outflow of blood into peripheral tissue following a
hemorrhagic event, novel neuroprotective therapies can be introduced.

15
1.3.2. Transient ischemic attack
A transient ischemic attack (TIA) is a brief episode of functional deficits resulting from a
focal ischemic incident, which is not permanent, with measurable behavior deficits typically
lasting less than one hour (Easton, J. D. et al., 2009). Recently, this type of injury has become
very important as means of predicting future strokes, and is a stepping stone in the initiation of a
variety of cognitive disorders. Individuals who experience a TIA are at nearly twice the risk of
experiencing a permanent stroke (Coutts, S. B. et al., 2012), and this type of injury has been
shown to be a common occurrence either following or initiating cerebral amyloid angiopathy
(Charidimou, A. et al., 2012; Mandybur, T. I., 1986; Smith, D. B. et al., 1985). This type of injury
also seems to be very hard to identify. Until recently (2012) the definition of a TIA included any
event that persisted for up to 24 hours, and tended to included incidents of hemorrhagic
transformation. This type of ischemic incident is currently understudied relative to other stroke
types, and agreement tissue infarction following these events is sparse.

1.3.3. Ischemic stroke
Ischemic strokes are more prevalent than any other form of stroke making up 87% of all
cases (Doyle, K. P. et al., 2008; Mozaffarian, D. et al., 2016). Ischemic stroke is the result of the
blockage of blood flow to neural tissue caused by an occlusion or hypo-perfusion of the
cerebrovascular network. This ischemic event limits the oxygen and nutrient supply to neural
tissue causing excitotoxcity, oxidative and nitrosative stress, and inflammation with proteolytic
activity (Brouns, R. & De Deyn, P. P., 2009). The heterogeneous nature of the event produces
variably sized lesions with deficits specific to the damaged neural tissue. The central component
of the stroke, or the stroke core, is a region of almost complete loss of blood flow and pronounced
rapid necrosis of neurons. The surrounding region, the penumbra, has graded regions of blood
flow reductions and variable loss of neurovascular cells (Kaufmann, A. M. et al., 1999). Cells
within this region have limitations to their oxygen and glucose supply and tend to undergo
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apoptosis if blood flow is not restored (Lipton, P., 1999). This region is the target of
neurotherapeutics, as damage to this region occurs in a much more delayed manner than in the
stroke core. By better understanding the mechanisms of cell death and inflammation in regions
surrounding the stroke core, neurological deficits and long-term disability associated with
ischemic stroke could be reduced substantially.

1.3.4. The ischemic cascade
The initiation of stroke pathophysiology (Figure 6) occurs with reductions in oxygen and
glucose transport to the CNS from the presence of an embolism, thrombosis, or systemic
hypoperfusion. As metabolic supply becomes progressively more limited, failure of ion pump
function, increases in excitotoxicity, reversal of metabolic transporters, production of oxygen and
nitrogen free radicals, and the release of proinflammatory cytokines and proteolytic enzymes all
occur (Liu, K. J. & Rosenberg, G. A., 2005; Moro, M. A. et al., 2005). The progression of these
events leads to necrosis (stroke core) (Linnik, M. D. et al., 1993; Nedergaard, M. et al., 1986)and
delayed apoptosis (penumbra) which further exacerbates pathology (Broughton, B. R. et al.,
2009; Ferrer, I. & Planas, A. M., 2003). Vascular reperfusion can also produce deleterious effects
leading to further production of proteolytic enzymes and free radicals (Aronowski, J. et al., 1997).
Hemorrhagic transformation can also occur allowing blood to pool in the brain parenchyma
further complicating treatment strategies and worsening prognosis (Fiorelli, M. et al., 1999;
Jickling, G. C. et al., 2014).
At the initiation of ischemia, loss of the brains ability to produce adequate levels of
adenosine triphosphate (ATP) results in functional dysregulation of various components of the
neurovascular unit (NVU) (Martin, R. et al., 1994). The brains limited capacity for the storage of
energy further exacerbates the impact of stroke. With neuronal ATP deprivation, the functional
capacity of membrane ion pumps is substantially diminished due to the reversal of
sodium/potassium pumps (Katsura, K.-i. et al., 1994). This reversal leads to increases in
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extracellular potassium and pathological neuronal depolarization (Longuemare, M. & Swanson,
R. A., 1995). Prolonged ischemia leads to widespread depolarization of neurons which can lead to
influxes in sodium and calcium, increasing extracellular glutamate, and producing excitotoxicity
(Rossi, D. J. et al., 2000; Rothman, S. M. & Olney, J. W., 1986). Extracellular glutamate can also
be increased through the reversal of excitatory amino acid transporters (EAAT) (Nicholls, D. &
Attwell, D., 1990), which normally work to maintain the homeostatic balance of glutamate
bioavailability (Shigeri, Y. et al., 2004). The rise in extracellular glutamate can also cause
polarity shifts in astrocytic endfeet and the loss of their association with blood vessels (Steiner, E.
et al., 2012).
Excitotoxicity is produced through the activation of N-methyl-D-aspartate (NMDA) and
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors leading to increases
in, and accumulation of, intracellular calcium (Choi, D. W., 1988; Meldrum, B. et al., 1985). This
rapid calcium increase further exacerbates the energetic load of the cell leading to mitochondrial
dysfunction and the continued depletion of ATP. Mitochondrial calcium overload also leads to
the release of apoptosis-inducing factor (AIF) which can lead to DNA fragmentation and cell
death (Kroemer, G. & Reed, J. C., 2000; Szydlowska, K. & Tymianski, M., 2010; Zhu, C. et al.,
2003). The p38 pathway is also stimulated through elevated levels of intracellular calcium during
ischemia (Yuan, S. Y., 2002). This can lead to the production of reactive oxygen specifics and the
upregulation of a variety of inflammatory pathways (Moro, M. A. et al., 2005).
The production of reactive oxygen and nitrogen species (ROS and RNS) during cerebral
ischemia is directly linked to the rapid and robust changes in mitochondrial respiration and health
(Beckman, J. S. et al., 1990). Reactive oxygen and nitrogen species refers to an oxygen and
nitrogen molecule with an unpaired electron. Their production leads to increases in transcription
of activator protein 1 (AP-1) and nuclear factor kappa-beta (Nf-κβ) (O'Neill, L. A. &
Kaltschmidt, C., 1997). These proteins are associated with apoptosis (AP-1) and proteolytic
enzyme transcription (Nf-κβ) (Gu, Z. et al., 2005; Murphy, G. et al., 1999). Free radicals (ROS
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Figure 6. Representative cartoon of the ischemic cascade of various pathological hallmarks.

and RNS) can also impact the activation of inflammatory proteases leading to exacerbation of
inflammation and BBB degeneration (Liu, K. J. & Rosenberg, G. A., 2005). As the
pathophysiology of stroke progresses, the resulting activation of numerous inflammatory
pathways unfolds along with the previously mentioned mechanisms of CNS damage. The
inflammatory process is produced through the release of cytokines, specifically interleukins,
tumor necrosis factor α (TNFα), and matrix metalloproteinases (MMPs) (Gasche, Y. et al., 1999;
Gong, C. et al., 1998; Xing, C. et al., 2014b). Interleukin 1β (IL-1β) and TNFα produces robust
activation of Nf-κβ (Barger, S. W. et al., 1995; Huang, J. et al., 2006). Nuclear factor kappa-beta
is the main transcriptional regulator of inflammatory responses to ischemia (Cechetto, D. F.,
2001). It has a central role in the further activation of cytokines, chemokines, adhesion molecules,
and even, anti-apoptotic factors (Liu, T. et al., 2017). One of its most prominent roles in ischemia
is the initiation of MMP transcription, specifically, MMP 3 and 9 (Rosenberg, G. A. et al., 2001;
Rosenberg, G. A. et al., 1996; Yang, Y. et al., 2011). Matrix metalloproteinases play a central role
in the degradation of the extracellular matrix, as well as the degradation of the basal lamina,
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which produces decreases in BBB tightness and resulting increases in paracellular leakage (Xing,
C. et al., 2014b).

1.4. Matrix metalloproteinases: Types, regulation and function
Matrix metalloproteinases are zinc-dependent proteolytic enzymes which begin as a propeptide and are activated through a variety of mechanisms to promote cellular, membrane, and
junctional reorganization in the central nervous system. The ability of MMPs to degrade
components of the extracellular matrix is a fundamental step in promoting synaptic remodeling,
initiating integrin signaling, promoting angiogenesis, and maintaining balance between pro- and
anti- inflammatory responses. As a result, MMPs are the focus of pharmacological interventions
across a broad spectrum of CNS disorders including stroke and neurodegenerative diseases.
Matrix metalloproteinases come in a variety of isoforms with overlap in the protein
structure of their catalytic domains. These catalytic domains all contain zinc and calcium ions
which promotes structural stability and enzymatic activity (Table 1). Nearly half of all MMPs
can also degrade fibronectin and aggrecan. Linker and hemopexin domains are also preserved
across most MMPs, with a couple of exceptions, which allow for the localization of the propeptide to various regions of the cell membrane. Substrate binding is determined by a docking
pocket of the catalytic domain. Slight variability in the composition and orientation of the protein
loops of MMPs provides substrate binding specificity. These subtle amino acid modifications in
protein and catalytic domains provides a means for categorizing the metalloproteinases.
In humans there are 23 MMP variants, however, over thirty total MMPs have been
distinguished across a variety of species and subdivided into categories. These categories are
based on the targets of protein degradation by MMPs, domain structure, and in certain cases
(membrane bound MMPs), localization within the cell. Although a wide range of overlap is
present between targets of various isoforms, these categories are helpful in delineating the
functional differences and specificities of these proteases.
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Table 1. Matrix metalloproteinase types and substrate targets. Gel (gelatin), PG
(proteoglycan), FN (fibronectin), Lam (laminin), Cad (cadherin), EL (elastin).
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1.4.1. Collagenases
The collagenases include MMP 1, 8, 13, and 18 which act on collagens 1, 2, and 3 as well
as 7, 8 and 10. The collagenases have been shown to play a role in cell migration through
fibronectin degradation, cell proliferation through the activation of protease activated receptors
(PAR), and have also been implicated in the invasive actions of cancer cells. Collagenases also
seem to have a role in wound healing through their release by neutrophils following chronic
inflammation and a resulting cleavage of scar forming connective fibrin proteins. These proteases
have substantial substrate binding overlap with membrane-type 1 MMP (MT1-MMP) which is
differentiated from collagenases due to in anchoring within the membrane. This form of MMPs
are also substantially influenced by integrin signaling.
Integrin signaling can occur through a variety of pathways, but the ability of these
signaling mechanism to initiate are driven by proteolytic actions on the ECM. In the case of the
collagenases, they act on fibronection allowing the exposure of integrin receptors and the
activation of focal adhesion kinases (FAK) (Forsyth, C. B. et al., 2002; Tremble, P. et al., 1995).
This activation leads to an increase in the transcription of the collagenases (among other things)
allowing for the reorganization of cellular components and cellular migration (Guan, J.-L., 1997).
It is thought that the main contributor to collagenase production is through stimulation of PI3K 
AKT pathway (Beier, F. & Loeser, R. F., 2010). Their involvement in integrin signaling,
however, is not unique. A variety of other MMPs (MT-MMPs, Gelatinases, and Stromelysins) are
also involved in integrin receptor exposure and signaling.

1.4.2. Stromelysins
The stromelysins consist of MMPs 3, 10, and 11. The stromelysins have catalytic and pro
domains very similar to that of the collagenases, however, they tend to degrade cadherins and
basement membrane proteins and not interstitial collagens. Stromelysins, specifically MMP 3,
have also been shown to increase the bioavailability of TNFα by degrading proteins that have
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maintained its cellular localization (Kim, Y. S. et al., 2005; Suzuki, K. et al., 1990). MMP 3 can
also interact with plasminogen, cleaving its catalytic domain, and potentially reducing its activity
(Lijnen, H. et al., 1998). This process can also occur with tissue inhibitors of metalloproteinases
(TIMPs) leading to the further activation of other MMPs. Finally, in MMP 3 knockout mice,
peripheral tissue has a limited capacity for wound closure, limiting wound healing (Bullard, K.
M. et al., 1999). This shows overlap in the biological effects of MMP 3 with collagenases (wound
healing) although they differentially impact wound healing (Saarialho-Kere, U. K. et al., 1993). It
should also be noted that although MMP 11 is technically considered a stromelysin due to its
domain composition (both pro and catalytic domains), yet, it seems to act more as a matrilysin
and it tends to be categorically placed in that group of metalloproteinases (Nagase, H. et al.,
2006).

1.4.3. Matrilysins
The matrilysins are made up of MMP 7 and 26 with some variation to the group coming
with the addition of MMP 11 due to its intracellular localization because of a lack of a hemopexin
domain. The lack of hemopexin domains in matrilysins has been thought to limit the ability of
TIMPs to inhibit this category of MMPs (Yong, V. W. et al., 2001). These also tend to act
intracellularly due to this unique structural difference. Matrix metalloproteinase 7 is normally
associated with the cleavage and activation of tumor necrosis factor α (TNFα) as well as the
degradation of E-cadherin (Black, R. A. et al., 1997; Noë, V. et al., 2001). The activity of
matrilysins is not normally associated with biological effects in the CNS.

1.4.4. Membrane-type MMPs
Membrane-type matrix metalloproteinases can be subdivided into
glycosylphosphatidylinositol anchored (GPI-anchored) and transmembrane type MMPs. These
are also referred to as MMP 14 – MMP 17 and MMP 24 and 25 as well as MT1-MMP – MT6-
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MMP. The variability in their names seems to come from the timing in which they were
discovered along with the discovery of variation in their membrane binding domains (which
occurred much later) (Itoh, Y. et al., 1999; Kojima, S.-i. et al., 2000; Takino, T. et al., 1995).
These proteinases are unique in that they have a furin recognition motif that allows for their
activation intracellularly with enzymatic activity occurring at the cell surface. Membrane-type
MMPs, excluding the GPI anchored MT-MMPs, also have the unique feature of binding and
activating MMP 2 which can produce local and robust enzymatic activity (Forsyth, P. et al., 1999;
Miyamori, H. et al., 2001). This interaction can also mediate the activation of MMP 9 in
perivascular space (Toth, M. et al., 2003). Membrane type 1-MMP can also function as a
collagenase, having the ability to degrade collagen 1-3. Importantly, under normal physiological
conditions, MT1-MMP has be shown to degrade CD44 (a glycoprotein involved in cell adhesion
and interaction) allowing for cellular migration (Kajita, M. et al., 2001). Similar cell migratory
properties are also associated with MT2- and 3-MMP (Hotary, K. et al., 2000). It should also be
noted that MT-MMPs have been shown to play a role in a variety of proteolytic activities beyond
the typical collagenolytic activity they are associated with (D'ortho, M. P. et al., 1997). It has also
be demonstrated that the removal of the transmembrane component of MT1-MMP renders MMP
2 inactive, however, a substantial amount of this literature has focused on cancer cell cultures
(Imai, K. et al., 1996; Yamamoto, M. et al., 1996).

1.4.5. Macrophage Elastases, Enamelysins, and CA-MMPs
As mentioned previously, there are a wide range of MMPs that can subdivided into
categories based on their substrate binding and domain composition. There are, however, a
number of MMPs that seem to either have cell-specific functions (macrophage elastases) (Werb,
Z. & Gordon, S., 1975), have a very specific origin and location (Enamelysins) (Bartlett, J. &
Simmer, J., 1999), or have novel pro-domains while maintaining normal MMP function (CAMMPs) (Pei, D., 1999). These MMPs include MMP 12 and 19 (Macrophage elastases), MMP 20
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and 21 (Enamelysins), and MMP 23 and 27 (CA-MMPs). Each of these group will be briefly
discussed, however, they have yet to be shown to have a substantial impact on CNS function
outside of the macrophage elastases. This is not to say that they do not play a role in CNS
physiology, however, evidence is limited.
The macrophage elastases have been shown to be an MMP found in both humans and
mice that is activated through the stimulation of macrophages. They have been implicated in
aortic aneurysms (Curci, J. A. et al., 1998), pathological process involving the peripheral
circulatory system (Molet, S. et al., 2005), and pro-inflammatory disease states (Liu, M. et al.,
2004). Matrix metalloproteinase 12 has also been shown to play a role in mediating macrophage
migration and responses to infection (Shipley, J. M., Wesselschmidt, R. L., et al., 1996). Matrix
metalloproteinase 19 has also been shown to have a robust impact on ECM degradation as it can
degrade laminin, gelatin, collagen 4, and fibronection. Matrix metalloproteinase 19 has also been
shown to autoactivate, but not through pro domain interactions. It is also unable to activate any of
the other MMPs (Stracke, J. O. et al., 2000).
Matrix metalloproteinases 20 and 21 are the Enamelysins (Caterina, J. et al., 1999)which
are found in developing teeth across a broad array of species. Little information is known about
these MMPs, but they have been shown to be controlled in a developmentally dependent manner
with reduced expression in late life. They have also been shown to form a complex with TIMP2
which tightly regulates the activity of MMP 20 (Bourd-Boittin, K. et al., 2004). Although their
name would imply some sort of role in enamel formation, knockout mice of MMP 20 have shown
no deficiency in enamel formation, but instead, reductions in the mineralization of teeth (Beniash,
E. et al., 2006).
The cysteine array MMPs are another group of under studied MMPs. This group of
MMPs includes MMP 23 and 27 with MMP 27 being found in chicken embryos. These MMPs
have a modification in their hemopexin domains producing cysteine rich domain as a replacement
(Pei, D., 1999). This modification to their hemopexin domain (or its exclusion) makes this type of
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MMP unique in that it is a transmembrane MMP (MT-MMP) and yet it is released upon cleavage
of its pro-peptide domain (Pei, D. et al., 2000). In the human and mouse little information exists
in regard to this particular category of MMPs.

1.4.6. Gelatinases
The gelatinases consist of MMP 2 and 9, which are also referred to as Gelatinase A and B
respectively. The gelatinases are structurally distinct in they contain a variable zinc binding site in
their catalytic domain as well as three fibronectin type 2 repeats in their catalytic domain which is
responsible for their substrate binding. As a result of the fibronectin repeats, the gelatinases bind
readily to gelatin and collagen (Shipley, J. M., Doyle, G. A., et al., 1996). The primary targets of
the gelatinases are laminin and collagens 4, 5, and 11. MMP 2 and 9 have some variability in
their abilities to degrade various forms of collagen with MMP 2, but not 9, having the ability to
digest collagens 1-3 (in a substantially weaker manner compared to the collagenases) (Patterson,
M. L. et al., 2001). Matrix metalloproteinase 2 is also unique in that its pro-peptide form interacts
with MT1-MMP at which time it localizes to the membrane and becomes activated (from
exposure of its catalytic domain) producing robust collagenolytic activity in a localized manner
(Itoh, Y. & Seiki, M., 2006). Under normal physiological conditions MMP 2 and 9 have been
shown to be involved in pericyte migration, angiogenesis, microvascular development and
synaptic plasticity (Huntley, G. W., 2012; Hurtado-Alvarado, G. et al., 2014;
Thanabalasundaram, G. et al., 2010; Verslegers, M. et al., 2013; Wang, X. et al., 2008).
During angiogenesis endothelial cells produce MMP 9 to allow for the breakdown of the
surrounding ECM and the migration of new cells to the location (Rundhaug, J. E., 2005). Matrix
metalloproteinase 9 has also been shown to play a role in neurite and process outgrowth of both
neurons and oligodendrocytes (Chambaut-Guerin, 2000; Oh et al 1999). Endothelial cells of
newly forming blood vessels have also been shown to express MMP 2 localized to regions of
degraded ECM. The regions also contained pericytes and had robust vascular endothelial growth
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factor (VEGF) suggesting an interplay between these cells and proteolytic activity at regions of
new vessel formation. A wide range of studies have also shown the gelatinases to be involved in
long term potentiation (Fragkouli, A. et al., 2012; Nagy, V. et al., 2006; Wang, X. et al., 2008),
synaptic reorganization (Kaliszewska, A. et al., 2011; Nishijima, T. et al., 2010), and the
activation of a variety of growth factors important for a wide range of functions (Lu, L. et al.,
2008; Penedo, L. A. et al., 2009; Zhao, B. Q. et al., 2006). As a result of their broad functional
impact, their dysfunction, or dysregulation, is associated with a wide range of neurological
disorders making the temporal dynamics of their activation important in disease processes.

1.5. Gelatinases during disease
Pathological increases in proteolytic activity are involved in numerous disease processes
of the central nervous system. These disease states share a lot of similar pathophysiological
processes including tight junction dysregulation, vascular leakage, oxidative and nitrative stress,
ECM degradation, and inflammation. Diseases such as Alzheimer’s disease, stroke, multiple
sclerosis, and traumatic brain injury have all been shown to have elevated MMP activity as a
component of their pathological progression. In particular, these disease states all show robust
increases in gelatinase activity.
The gelatinases have been shown to lead to BBB breakdown and neuronal cell death in
Alzheimer’s disease (Bell, R. D. et al., 2012; Lee, J. M. et al., 2003; Schultz, N. et al., 2014) as
well as being potential biomarkers for disease progression (Lorenzl, S., 2003). In multiple
sclerosis, MMP 9 has also been shown to be elevated in patients during and after relapse, which
may contribute to the progression of the disease (Leppert, D. et al., 1998). The gelatinases have
also been explored as biomarkers for the prediction of MS severity (Benešová, Y. et al., 2009). In
traumatic brain injury, degradation of junctional components of the BBB by the gelatinases leads
to increases in infarct volume and exacerbates cerebral edema (Hadass, O. et al., 2013;
Shigemori, Y. et al., 2006). In mouse models with genetic knockouts of MMP 9, lesion volume is
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significantly reduced making the gelatinases a potential target for reducing disability associated
with TBI (Mori, T. et al., 2002; Wang, X. et al., 2000). Finally, the gelatinases have been shown
to predict complications, hemorrhagic transformation, and death in stroke (Inzitari, D. et al.,
2013; Montaner, J., 2003). In the following sections gelatinase activity, and cell-specific
contributions to this activity, will be explored in the context of stroke, and the potential for their
inhibition as a therapeutic intervention will also be discussed.

1.5.1. Gelatinase activity during stroke
As mentioned previously, the gelatinases, and in particular MMP 9, have been shown to
predict the severity of stroke progression as well as complications related to the disorder. The
influence of these proteolytic enzymes, however, is much more complicated. Variability in the
timing of gelatinase activation can have a dramatically different impact on CNS health and the
progression of the ischemic cascade (Rosenberg, G. A. et al., 1996). A variety of inflammatory
factors can lead to the upregulation of gelatinase activity, and as a result, increases in the severity
of damage from the injury (Xing, C. et al., 2014a). Astrocytes, leukocytes, neurons, pericytes,
endothelial cells and microglial cells have all been shown to produce the gelatinases under
various circumstances either related to the repair of blood vessels or angiogenesis following
injury, or during the progression of disease pathophysiology (Bergers, G. et al., 2000; Gidday,
Jeffrey M et al., 2005; Machida, T. et al., 2015; Zhao, Bing-Qiao et al., 2006). Matrix
metalloproteinases, in general, have also been the target of therapeutic intervention in clinical
trials, but temporal and isoform specific interventions have largely been ignored until recently
(Amar, S. & Fields, G. B., 2015).
Matrix metalloproteinase 2 and 9 are thought to be the proteolytic enzymes responsible
for BBB opening during ischemia (Yang, Y. et al., 2007). During the progression of the acute
phase (hours to days) of stroke elevated levels of pro-MMP 9 have been demonstrated as early as
two hours after occlusion (Gasche, Y. et al., 1999). These elevated levels of pro-MMP 9 have
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been reported as transient increases, lasting for up to three days, but with a second wave of
activation occurring much later (Zhao, Bing-Qiao et al., 2006). It has also been shown that these
increases correspond to a resulting increase in the activated form of MMP 9 during the early
progression of stroke (as early as three hours) (Fujimura, M. et al., 1999; Rosenberg, G. A. et al.,
1996). As increases in activated MMP 9 occur, modifications to tight junction proteins are also
seen. Early degeneration of occludin and zonula occludens – 1 has been demonstrated to
correspond with this elevation in MMP 9 activity, both as overall reductions in protein expression
(Yang, Y. et al., 2007), and as gaps in an otherwise continuous structure (Bauer, A. T. et al.,
2010). These junctional modifications have a resulting impact on the progression to tissue
infarction. In humans, elevated levels of MMP 9 are also associated with increases in infarct
volume in patients with strokes (Horstmann, S. et al., 2003; Montaner, J. et al., 2001; Rosell, A.
et al., 2005). Finally, the genetic knockout of MMP 9 shows neuroprotection in animal models of
ischemia while knockout of MMP 2 seems to have little influence (Asahi, M. et al., 2001; Suofu,
Y. et al., 2012).
The neuroprotection of isoform specific genetic manipulations may speak to the differing
roles of proteolytic responses to ischemia, but moving toward the later phases of the disease,
these enzymes may have a biphasic role and their loss may prove harmful. As early as the subacute phase (days to weeks) of stroke, neurovascular remodeling has been demonstrated. During
this period, elevated levels of MMP 2 and 9 have been shown to be necessary for angiogenesis
through activation of VEGF and potentially other trophic factors (Bergers, G. et al., 2000; Zhao,
B. Q. et al., 2006). Matrix metalloproteinase 2 and 9 has also been shown to be required for the
recruitment of new cells to regions of injury in stroke (Lee, S.-R. et al., 2006; Wang, L. et al.,
2006) as well as neurite outgrowth similar to that seen during development. Evidence is limited as
to the impact of gelatinase inhibition in later phases of stroke, but novel therapeutics have
progressed to address their early deleterious effects.
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1.5.2. Mechanisms of Ischemic Gelatinase Activation
The initiation of inflammation during ischemia is one of numerous processes occurring
concurrently during the pathophysiology of stroke. With the invasion of immune cells and
pathological activation of signaling cascades, transcriptionally derived proteins begin to shape
cellular and extracellular environments. Tumor necrosis factor α and IL-1β can activate interferon
regulatory factor 1 (IRF1) leading to the production of inducible nitric oxide synthase (iNOS) as
well as the pathological initiation of the p38 apoptotic pathway (Saura, M. et al., 1999;
Takahashi, Y. et al., 2014a). This activation can lead to DNA damage as well as the subsequent
activation of cytochrome c and resulting apoptosis (Hüttemann, M. et al., 2012). The activation of
p38 can also lead to AP-1 and subsequent transcription of MMPs (Woo, M. S. et al., 2008). This
is simply one of a number of biochemical pathways that can lead to the transcription of MMPs
during ischemia. In particular, the gelatinases are upregulated during the ischemic cascade, but
their activation is a complex interplay between available pro-peptides and the numerous
activators that are present in the ischemic environment (Rosell, A. et al., 2006; Zinnhardt, B. et
al., 2015).
As mentioned above the activation of MMP 2 can occur through its association with
MT1-MMP and is thought to make MMP 2 a constitutively present MMP. The activation of
MMP 2 (Murphy, G. et al., 1999) as well as MMP 3 (HAHN‐DANTONA, E. et al., 1999;
Ramos-DeSimone, N. et al., 1999) can lead to the activation of MMP 9. Matrix metalloproteinase
2 and 3 have been shown to be elevated early during the pathogenesis of ischemia which can then
lead to the cleavage and activation of MMP 9 (Rosenberg, G. A. et al., 2001; Rosenberg, G. A. et
al., 1996). During ischemia, endogenous plasminogen activator is also elevated which can lead to
pronounced activation of MMP 9 (Ahn, M. Y. et al., 1999; Hosomi, N. et al., 2001). Reductions
in hemorrhagic transformation have been shown when this mechanism of MMP 9 activation is
prevented (Pfefferkorn, T. & Rosenberg, G. A., 2003). Finally, ATP depletion and the formation
of reactive oxygen and nitrogen species have been shown to directly activate MMP 9 through a
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variety of different nitric oxide mediated pathways (Lakhan, S. E. et al., 2013; Liu, K. J. &
Rosenberg, G. A., 2005; Okamoto, T. et al., 2001), however, it is important to first understand the
mechanisms leading to the transcription of MMP 9 during ischemia.

1.5.3. Transcriptionally derived gelatinases
The MMP 9 promoter is unique from the MMP 2 promoter in that AP-1 can act as a
transactivator of the gene allowing for its transcription in a rapid a robust manner based on the
bioavailability of AP-1 and Nf-κβ (Yan, C. & Boyd, D. D., 2007). The functional Nf-κβ site on
the MMP 9 promoter makes it responsive to TNFα. Matrix metalloproteinase 9 mRNA is also
stabilized through integrin signaling which extends the window for pro-MMP 9 translation (Iyer,
V. et al., 2005). During inflammation the availability of MMP 9 activators is substantially
increased meaning this increase in MMP 9 mRNA lifespan can lead to an even greater presence
of MMPs. This, in turn, can lead to degradation of the ECM leading to a continuation of integrin
receptor exposure and activation. Increases in MMP 9 transcription can also occur through the
activation of TGFβ, MMP 2, Ang2/Tie2 signaling, and a variety of growth factors (Yan, C. &
Boyd, D. D., 2007) which all feedback into a loop of pro-MMP 9 transcription. With elevated
levels of pro-MMP 9 (and the cytokines, growth factors, and downstream effectors to produce
more) available from transcriptional activity within the ischemic environment, rapid processes
lead to MMP 9 activation and subsequent damage from ischemic injury. Some of the most rapid
processes leading to MMP 9 activation within the ischemic environment are through reactive
nitrogen species (RNS).

1.5.4. S-Nitrosylation
S-nitrosylation is the covalent attachment of nitric oxide (NO) molecules to sulfhydryl
residues on proteins at cysteine thiol groups (Gow, A. J. et al., 2002). This process is a posttranslation modification of proteins and is maintained through the homeostatic balance of
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environmental pH, localization of proteins with NO, and the orientation and exposure of
sulfhydryl residues (Martínez-Ruiz, A. et al., 2011). Disorders that change the acidity of the
cellular environment and lead to increases in the presence of NO can increase the presence of
reactive S-nitrosylated species (RSNO) (Bryan, N. S. et al., 2004). Increases in the bioavailability
of NO can occur through dysregulation of the three isoforms of nitric oxide synthase (NOS)
which includes inducible NOS, endothelial NOS, and neuronal NOS. Endothelial NOS and nNOS
have both been shown to lead to robust NO production during ischemia as levels of calcium begin
to rise and mitochondrial respiratory chains begin to fail (Jiang, Z. et al., 2014; Moro, M. A. et
al., 2005; Willmot, M. et al., 2005). Ischemia also leads to the expression of iNOS which further
exacerbates the elevation of available NO (Li, Y. et al., 2013; Melillo, G. et al., 1995).
Elevated levels of NO have been shown to lead to the activation of MMP 9 via Snitrosylation during ischemia (Gu, Z. et al., 2002). In the aforementioned study, MMP 9
activation was mediated through the binding of RSNO to pro-MMP 9 as availability of NO
increased during ischemia. The NOS responsible for the elevated NO during this process was
suspected to be nNOS. Importantly, this study also demonstrated that the activation of MMP 9,
leading to neuronal apoptosis during ischemia, was indeed a function of S-nitrosylation of MMP
9 rather than the simple production of peroxynitrite, and subsequent superoxide formation,
leading to mitochondrial failure. Although this represents one mechanism by which MMPs can
become activated during ischemia, there are concurrent pathways by which RNS/ROS can lead to
the rapid activation of MMP 9 and further exacerbation of BBB degeneration.

1.5.5. S-glutathionylation
Glutathione (GSH) is an important intracellular peptide that is involved in the regulation
and maintenance of homeostatic oxidative signaling through the scavenging of NO and oxidative
molecules. Through the donation of electrons GSH can eliminate reactive oxygen and nitrogen
species as well as reducing nitrosylated proteins, and as a result, it is important in the protection
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against nitrative and oxidative stress (Dringen, R. et al., 2000; Klatt, P. & Lamas, S., 2000).
During ischemia, reductions in available ATP substantially limits the production of GSH which
can exacerbate pathology in an already dysfunctional system. It has also been shown that
reductions in GSH can lead to increases in excitability of NMDA receptors (Steullet, P. et al.,
2006) which could potentially lead to increases in excitotoxicity. Glutathione, or its product of
oxidation, glutathione disulfide, can also interact with a variety of proteins in a process called Sglutathionylation or S-thiolation (Thomas, J. A. et al., 1995). This process can lead to the
activation of matrix metalloproteinases, and has also been shown to occur through the byproduct
of GSH and peroxynitrite, GSNO2 (Giustarini, D. et al., 2004; Wu, J. et al., 2001). Little is known
about the specific MMPs that are activated through this pathway or the conditions that could elicit
such an effect, however, some evidence has shown S-glutathionylation as a process involved in
MMP 2 activation (Migita, K. et al., 2005; Okamoto, T. et al., 2001)

1.5.6. Tyrosine nitration
Tyrosine nitration can occur through a wide variety of pathways all involving the
production of nitrogen dioxide (NO2) and subsequent interaction with protein tyrosine residues
(Gow, A. J. et al., 2004); the most typical substrate leading to NO2 production is peroxynitrite
(Sampson, J. B. et al., 1996). As mentioned previously, the generation of this oxidative product is
commonplace in ischemic injury and accounts for a substantial amount of pathological damage
when its production, oxidation, reduction and elimination are not held in balance. As ROS and
RNS production becomes elevated nitrogen dioxide products can interact with proteolytic
enzymes resulting in their activation (Pacher, P. et al., 2007). This mechanism has been shown to
result in the activation of MMP 9 through the induction of iNOS, subsequent elevations in NO,
progressive translocation of NF-κβ, and the continuation of available pro-MMP 9 (Wang, H. H. et
al., 2011). This mechanism could account for another means of rapid MMP 9 activation during
ischemia, but novel insights into this process are still forthcoming. Working to understand these

33
rapid processes that can lead to MMP activation and dysfunction of the BBB during ischemia
could allow for more targeted interventions in individuals suffering for this type of pathology.

1.5.7. Gelatinases as therapeutic targets
Initial therapeutics targeting MMPs were used to attempt to prevent the progression of a
variety of cancers. These early MMP therapeutics looked to target the proteases as a whole rather
than in an isoform specific fashion (Bissett, D. et al., 2005; Ferrario, A. et al., 2004; Heath, E. I.
et al., 2006). These treatments produced a wide range of undesirable side effects and testing came
to a halt. More recently, a drug (AZS1236) targeting MMP 9 and 12 was used to attempt to
reduce TNFα levels in patients with chronic obstructive pulmonary disease (COPD) (Dahl, R. et
al., 2012). Levels of TNFα were not reduce, but patients tolerated the drug, suggesting that it
could be used in other disorders.
In ischemic stroke only one approved treatment currently exists, tissue-plasminogen
activator (tPA). The window for the application of this treatment is around three hours following
an ischemic event. Anything beyond this window may worsen outcomes through hemorrhagic
transformation (Disorders, N. I. o. N. & Group, S. r.-P. S. S., 1995; Tilley, B. C. et al., 1997). The
limited widow for tPA administration severely reduces the number of patients that can receive
treatment. By extending this window, BBB preservation and restoration of glucose and oxygen
supply could be achieved. This extension may be achievable through the use of MMP isoform
(specifically MMP 9) specific inhibitors or therapeutic interventions that prevent MMP 9
upregulation. One of these treatments that has recently been used is hypothermia. In mild
hypothermia levels of both MMP 2 and 9 have been shown to be diminished, resulting in
preservation of basal lamina (Hamann, G. F. et al., 2004; Lee, J. E. et al., 2005). Although MMP
2/9 inhibitors have not been used in the context of clinical stroke, previous attempts at their
inhibition may demonstrate the need for cell and isoform specific targets of their inhibition.
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1.6. Pericytes as targets for therapeutic stroke intervention
Pericytes have been shown to play a crucial role in maintaining BBB integrity and
stability through constant signaling with the endothelium (Armulik, Annika et al., 2010; Gaengel,
K. et al., 2009; von Tell, Desiree et al., 2006). Disruptions in their signaling has been shown to
produce modifications in barrier integrity leading to transcellular leakage, and genetic
modifications leading to reductions in pericyte numbers has been shown to lead to the formation
of a leaky BBB (Lindahl, P., 1997). Pericytes has also been shown to respond dramatically to
ischemia leading to elevated levels of matrix metalloproteinase, shifts in pericyte/endothelial
signaling, and constriction of blood vessels (Hall, C. N. et al., 2014; Machida, T. et al., 2015;
Mandriota, S. J. & Pepper, M. S., 1998; Zozulya, A. et al., 2008). This type of response to
ischemia makes pericytes an interesting pharmacological target for therapeutic intervention, but
more research is needed to understand the spatiotemporal dynamics of pericyte pathology during
the pathophysiological process of ischemic injury.

1.7 Research hypothesis and objectives
The goal of this project is to determine the role of pericytes in BBB degeneration during the
early stages of ischemic injury, and to determine the biochemical mechanisms by which pericytes
influence BBB degeneration. The central hypothesis driving this work is that pericytes play an
active role in BBB opening during the early stages of ischemic injury through proteolytic
degradation of the capillary wall. Aim 1 is to test the hypothesis that MMP 9 activity is involved
in pericyte responses to microvascular ischemic injury in vivo. Aim 2 is to test the hypothesis that
nitric oxide plays a crucial role in the early activation of MMPs during pericyte-specific BBB
breakdown during ischemia. By expanding on the current knowledge of pericyte and proteolytic
responses to ischemia, potential novel approaches to pharmacological intervention could be
explored to expand the window for thrombolytic treatments in stroke.
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2.1 Introduction
The blood-brain barrier (BBB) is a highly selective vascular structure that prevents harmful
blood-borne substances from entering the brain (Sandoval, K. E. & Witt, K. A., 2008). Increased
BBB permeability worsens stroke outcome by exposing neurons to blood components, increasing
tissue edema (Larrue, V. et al., 1999), and limiting the window for thrombolytic treatment (Desilles,
J. P. et al., 2013; Hawkins, B. T. & Davis, T. P., 2005). Cerebral pericytes may play a role in BBB
changes after stroke, as they are essential for proper formation and maintenance of the BBB in the
normal brain (Lui, S. et al., 2012; Winkler, E.A. et al., 2011). Their continuous signaling with the
endothelium promotes normal tight junction development, and regulates vesicular trafficking and
immune cell infiltration across the endothelium (Armulik, A. et al., 2005; Ben-Zvi, A. et al., 2014;
Daneman, R. et al., 2010b). An inability to recruit pericytes to the endothelium in embryonic lethal
PDGFB or PDGFRβ knockout mice results in severe vascular abnormalities (Hellström, M. et al.,
1999), plasma leakage and microaneurysm formation (Lindahl, P. et al., 1997). A partial congenital
loss of PDGFRβ signaling allows animals to survive to adulthood, but progressive BBB
impairments increase with age resulting in neural dysfunction and cognitive decline (Bell, R.D. et
al., 2010). Perturbation of pericyte signaling during adulthood results in increased endothelial
transcytosis, indicating that pericytes maintain BBB function even after stable integration into the
vasculature (Armulik, A. et al., 2010). Furthermore, a polymorphism in the Foxf2 gene, which is
physiologically important for pericyte regulation of the BBB (Reyahi, A. et al., 2015), increases
the risk of stroke in humans (CHARGE et al., 2016).
While BBB dysfunction caused by genetically induced defects in pericyte signaling has
been well studied, it is less clear how normally developed pericytes in the adult brain respond to
acute ischemia. Early ultrastructural studies have shown that some pericytes migrate from the
endothelium during ischemia and traumatic brain injury (Dore-Duffy, P. et al., 2000; Duz, B. et al.,
2007; Takahashi, A. et al., 1997). More recent work has suggested that capillary pericytes die earlier
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than other cells of the neurovascular unit during stroke (Hall, C. N. et al., 2014). The most well
studied aspect of this vulnerability is the effect of aberrant contraction of pericytes (or closelyrelated smooth muscle cells), which can influence capillary diameter and the quality of cerebral
blood flow during reperfusion (Attwell, D. et al., 2015; Fernández-Klett, F. et al., 2010; Hall, C. N.
et al., 2014; Hill, R. A. et al., 2015; Peppiatt, C. M. et al., 2006; Yemisci, M. et al., 2009). However,
another consequence of early pericyte death could be BBB disruption, which is relatively
unexplored. Cultured pericytes have recently been shown to produce matrix metalloproteinases
(MMP) (Thanabalasundaram et. al., 2010; Takahashi et. al., 2014), which are key mediators of
BBB disruption during stroke (Barr, T. L. et al., 2010; Yang, Y. et al., 2007) and during small
vessel disease in dementia (Weekman, E. M. & Wilcock, D. M., 2015). In particular, various
inflammatory signaling cascades can induce pericyte MMP-9 expression in vitro (Machida, T. et
al., 2015; Takata, F. et al., 2011) and in vivo (Bell, R.D. et al., 2012; Gurney, K. J. et al., 2006).
This suggests that unlike their supportive roles during normal brain function, pericytes may open a
route for vascular leakage by enhancing MMP activity during ischemia.
Here, we used in vivo two-photon microscopy to study the relationship between pericytes,
MMP activity and BBB leakage during ischemia within the cortical capillary bed (Shih, A. Y. et
al., 2013; Taylor, Z. J. et al., 2016). We occluded a small region of the capillary bed by
photothrombosis to better preserve imaging quality. We further imaged transgenic mouse lines
expressing fluorescent reporters specifically in pericytes to unambiguously identify these
structurally elaborate cells and their ovoid-shaped somata (Hartmann, D.A et al., 2015). Finally,
we used a FITC-conjugated gelatin probe to detect gelatinase activity (MMP-2/9) in vivo with high
spatiotemporal resolution. Our findings show that ischemia results in rapid (tens of minutes) and
localized activation of MMP-9 and plasma leakage preferentially where pericyte somata adjoin the
capillary wall. These results provide strong evidence that pericytes are contributors to early BBB
degradation during ischemia.
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2.2. Methods and Materials
2.2.1. Mice
TdTomato reporter mice (Ai14) on a C57BL/6 background were purchased from Jackson
Labs (stock no. 007914) (Madisen, L. et al., 2010). These mice were bred with two different Cre
driver lines to achieve transgene expression in pericytes: PDGFRβ-Cre mice (a generous gift from
Volkhard Lindner from the Maine Medical Center Research Institute in Portland, Maine)(Cuttler,
A. S. et al., 2011) and NG2-CreER mice (Jackson Labs stock no. 008538)(Zhu, X. et al., 2011).
Mice were maintained in standard cages on a 12 hour light-dark cycle, and housed 5 or less per
cage. Following any surgical procedure, mice were housed singly. Both male and female mice were
used, and all mice used were between 2 to 5 months of age. To induce transgene expression in
NG2-CreER mice, tamoxifen dissolved in corn oil:ethanol (9:1) was injected intraperitoneally at a
dose of 100 mg/kg, every 24 hours for 5 consecutive days (Madisen, L. et al., 2010). These mice
were then imaged within 2 weeks after the final tamoxifen injection.

2.2.2. Surgery
Polished and reinforced thinned-skull windows (PoRTs)(Shih, A. Y. et al., 2012) or skullremoved, dura-intact craniotomies (Mostany, R. & Portera-Cailliau, C., 2008) were generated over
the sensorimotor cortex to achieve optical access for two-photon imaging. When intracortical
injections of FITC-gelatin and other drugs were required (see below), craniotomies were generated
and animals were imaged immediately after sealing the craniotomy with a coverslip. Otherwise,
imaging was conducted the day after PoRTS window generation. Anesthesia was induced with
isoflurane (Patterson Veterinary) at 3% mean alveolar concentration in 100% oxygen (AirGas Inc.)
and maintained at 1 to 2% during surgery. Body temperature was maintained at 37 oC with a
feedback-regulated heat pad. All animals were administered buprenorphine for analgesia prior to
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surgery at a concentration of 0.025 mg/kg. These procedures were approved by the Institutional
Animal Care and Use Committee at the Medical University of South Carolina.

2.2.3. In vivo two-photon microscopy
Two-photon imaging was performed with a Sutter Moveable Objective Microscope and a
Coherent Ultra II Ti:Sapphire laser source. Excitation was 975 nm for imaging FITC-dextran and
tdTomato. Excitation was 800 nm for experiments involving FITC-gelatin and Texas red-dextran.
In the latter case, excitation was tuned to 975 nm to capture tdTomato fluorescence at the start of
each experiment. Green and red emission was simultaneously collected using ET525/70m and
ET605/70m filter sets, respectively (Chroma Corp.). Throughout the duration of imaging, mice
were maintained under light isoflurane (0.75%) supplied in medical air (20-22% oxygen and 78%
nitrogen, moisturized by bubbling through water; AirGas Inc.). Pulse oximetry (MouseOx; Starr
Life Sciences) was used to monitor blood oxygen saturation and heart rate to ensure that
cardiovascular function was normal during imaging.
Procedures for blood flow imaging and analysis have been described previously (Shih, A.
Y. et al., 2012). Briefly, the blood serum was labeled by infraorbital vein injection of 0.025 mL of
FITC-dextran (2 MDa, FD2000S; Sigma-Aldrich) or Texas red-dextran (70 kDa, D-1830; Life
Technologies) prepared at a concentration of 5 % (w/v) in sterile saline. A 4-X, 0.13 NA air
objective lens (UPLFLN 4X; Olympus) was used to generate vascular maps of the entire window
for navigational purposes. High-resolution imaging was performed using a water immersion 20-X,
1.0 NA objective lens (XLUMPLFLN 20XW; Olympus). Tissue volumes sampled at high
resolution were 211 μm x 211 μm x 150 μm in the x, y and z planes, respectively. Lateral sampling
(x,y) was 0.41 µm per pixel and axial sampling (z) was 1 µm per pixel.
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2.2.4. Photothrombotic occlusions
For restricted photothrombotic occlusion of capillaries, a focused green laser (1 mW, 20
μm diameter at focal plane) was applied directly to the superficial capillary bed (avoiding pericyte
somata), immediately following retro-orbital vein injection of ~25-50 μL of Rose Bengal, prepared
at 1.25% (w/v) in sterile saline. This led to diffuse irradiation of surrounding capillaries, resulting
in loss of capillary flow and gradual BBB leakage. We titrated the extent of capillary occlusion by
modifying the duration of irradiation while keeping intravenous Rose Bengal dose fixed. The
experiments in this study involved a 25 second green laser irradiation. On rare occlusions (2 of 56
occlusions), the photothrombosis led to immediate BBB damage (< 5 minutes post-occlusion),
likely due to damage of a larger venule or arteriole. These data were omitted from the analyses.

2.2.5. Quantification of capillary leakage sites
Vascular leakage was quantified from 3-D renderings of the FITC-dextran labeled green
channel using Imaris 7.7 software (Bitplane), and also confirmed in 2-dimensional images by
scrolling through two-photon image stacks with Fiji software. Leakage events were defined as the
localized permeation of FITC-dextran from the intravascular space into the surrounding
parenchyma. Leakage sites typically possessed an intensely fluorescent focus surrounded by more
diffuse cloud of fluorescence. The position of the leakage focus was first established by visual
inspection, and then the second, tdTomato-positive imaging channel was used to determine its
position relative to a pericyte soma. To be counted as a soma-specific event, the focus of the leakage
site needed to be within 3 µm from the edge of a pericyte soma at its first observation following
photothrombosis. This offered a ~5% error margin on either side of a pericyte soma, considering
that the median length of capillary segments in cortex is 50 μm (Blinder, P. et al., 2013). At each
imaging time-point, leakage sites associated with a pericyte soma (pericyte) or not associated (nonpericyte) were counted to obtain a cumulative tally over time for each site of photothrombotic
irradiation. The rate of leakage site formation was then determined for pericyte soma and non-
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pericyte groups by performing a linear regression of the time-course data, and calculating the slope
of the fit.
In a subset of leakage events, we quantified the spatial extent of capillary leakage plumes.
These analyses were performed on 3-D renderings of the FITC-dextran labeled channel (Figure 7).
A string of 16 ROIs (with dimensions 8 μm x 8 μm x 16 μm in the x, y and z planes, respectively)
were placed along the capillary of interest, and the volume of FITC in each ROI was measured
before and after ischemia. Regardless of the position of pericyte somata, the ROI with the highest
FITC-dextran volume after occlusion was centered at ROI 8. If a tdTomato-positive pericyte soma
partially resided within the central ROIs (ROIs 7-9), the leakage site was categorized as a pericyte
soma-specific leakage event. All other cases were categorized as non-pericyte soma events.

2.2.6. In vivo gelatin zymography
A FITC-gelatin probe (Bozdagi, O. et al., 2007)(DQ-Gelatin, D12054; Life Technologies),
diluted to a concentration of 1 mg/mL in sterile PBS, was pressure injected into the cortex using a
pulled glass pipette (10-20 µm tip diameter). The pipette tip was lowered 250 µm into the cortex
with a Sutter MP-285 manipulator following the removal of a circular portion of skull (~2 mm)
over the somatosensory area. A small excision was made in the dura mater using a 26-gauge syringe
needle tip for entry of the glass pipette. FITC-gelatin was injected over 5 minutes using a
Picospritzer (10-20 ms pulses, 5-15 psi, 0.5-2 Hz pulse frequency) until 200 nL was delivered. The
injection pipette was then left in place for 10 minutes before removal from the cortex. The
craniotomy was then overlaid with 1.5% agarose followed by a circular coverslip. The coverslip
was fixed in position with dental cement prior to two-photon imaging.
FITC-gelatin labeled cells were quantified in image stacks using Fiji software. Cell bodies
that were positive for FITC-gelatin were defined as cells with 35% greater fluorescence intensity
than the surrounding neuropil. Cells that co-localized with pericyte somata (tdTomato) were
counted as FITC-gelatin positive pericytes. Areas of heightened FITC-fluorescence that did not co-
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Figure 7. Spatial profile of capillary leakage at pericyte soma and non-soma locations. a, Schematic showing
leakage site occurring at a pericyte soma and 16 ROIs used for the quantification in c. ROI dimensions were
8_8_16_m in the x-, y-, and z-planes. The ROI of greatest leakage volume was placed at the central ROI (ROI 8).
b, Representative 3-D renderings of intravenous dye extravasation at a pericyte soma(red arrow). ROIs (purple,
showing actual volume occupied by intravenous dye) were strung along the capillary segment to quantify the
volume of dye at preocclusion and 30 min postocclusion. The site of plasma leakage is shown with a white arrow.
c, Mean intravenous dye volume per ROI for five pericyte soma leakage sites (over three mice). The location of
the pericyte somata, from the TdTomato channel, corresponds with the ROIs with the greatest volume of
extravisated dye. The green trace is data from the specific leakage site shown in b. *p_0.05 and **p_0.01 denote a
significant volume increase from preocclusion values for the same ROI; multiple paired t tests. ROI 3, p_0.033;
ROI 6, p_0.012; ROI 7, p_0.003; ROI 8, p_0.012; ROI 9, p_0.019; ROI 10, p_0.035. Data are shown as the
mean_SEM. d–f, Equivalent analyses shown in panels (a– c) for five leakage sites (over three mice) occurring in
the absence of a pericyte soma. In f, pericyte somata for four of five cases were present in the sampled regions, but
the positions of these somata were not correlated with the peak leakage volume. *p_0.05 and **p_0.01 denote a
significant volume increase from preocclusion values for the same ROI; multiple paired t tests. ROI 1, p_0.031;
ROI 7, p_0.015; ROI 8, p_0.001; ROI 9, p_0.042. Data shown as the mean_SEM.

localize with pericyte somata, but exhibited some cellular morphology, were counted as FITCgelatin positive non-pericytes (Figures 11, 12). For studies using MMP-9 knockout mice (Jackson
Labs stock no. 007084) and C57Bl/6 controls (Jackson Labs stock no. 000664), two-photon image
stacks covering a 7 µm thickness ~75 μm below the pia were maximally projected. The
fluorescence intensity across the entire image field was quantified using Fiji software with no
discrimination for specific cell types.
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2.2.7. Matrix metalloproteinase inhibition: Systemic administration
GM6001 and SB-3CT was administered intraperitoneally at concentrations of 100 mg/kg
(Lee, S. R. et al., 2006) and 25 mg/kg (Gu, Z. et al., 2005), respectively. Both compounds were
first dissolved in pure DMSO, and then polyethylene glycol (PEG) and PBS were added to
complete the vehicle (38% DMSO, 31% polyethylene glycol, 31% PBS). Since a high level of
DMSO was required to completely dissolve the compounds, we also included a vehicle only
injection group. Intracortical injections. Isoform-specific inhibitors of gelatinases were coinjected with FITC-gelatin since their ability to pass the BBB has not been studied in detail. These
included the MMP-2 inhibitor Oleoyl-N-Hydroxylamide (444244, EMD Millipore; MMP-2
inhibitory constant (Ki) = 1.07 μM, MMP-9 Ki > 50μM,), and MMP-9 inhibitor C27H33N3O5S
(444278,

EMD

Millipore;

MMP-9

Ki=5nM,

MMP-1

Ki=1.05mM,

and

MMP-13

Ki=113nM)(Smith, A. C. et al., 2014). Both compounds were first dissolved in pure DMSO, and
then diluted to working concentrations in 1 mg/mL FITC-gelatin in PBS. A total of 5 pmol of the
MMP-2 inhibitor or 0.02 pmol of the MMP-9 inhibitor were injected per animal. These amounts
were calculated to be ~20-times above the Ki for the target isoform, to account for dilution once
injected into the cortex, but well below brain concentrations that could non-specifically affect other
MMP isoforms. All imaging studies were performed within the first 2-3 hours following drug
injection. A vehicle injection group was not included for intracortical injection experiments because
the final DMSO concentration was negligible (0.24% v/v). No animals died as a result of drug
administration in these studies. While no randomization of animals was used during data collection,
the analyses were performed with the rater blinded to treatment groups.

2.2.8 Statistics
All statistical analyses were performed using custom code written with MATLAB or SPSS
software. Statistical details are provided in the legend of each figure. Our sample size is similar to
previously reported studies using related techniques (Shih, A. Y. et al., 2013; Taylor, Z. J. et al.,
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2016). The normality of data sets was examined using the Lilliefors test to decide upon the use of
parametric or non-parametric analyses.

2.3. Results
2.3.1. Induction of capillary ischemia in mouse cortex using targeted photothrombosis.
We established a highly reproducible model of capillary ischemia by inducing
photothrombotic occlusion of superficial cortical capillaries in vivo (Figure 8a). A high molecular
weight fluorescent dye (2 MDa FITC-dextran) was first intravenously (i.v.) injected to label the
blood plasma for imaging. Following a subsequent i.v. injection of the photosensitizing agent, Rose
Bengal, the cortical surface was briefly irradiated with a focused green laser. The evolution of
capillary flow and leakage was then tracked with two-photon microscopy over a period of 3 hours
(Figure 8b, c). The irradiation led to immediate cessation of flow in a subset of capillaries within
the imaging field (~10 non-flowing capillary segments in a 0.007 mm3 imaging volume containing
~ 20 total capillary segments, where “segment” is defined as a capillary region between two branch
points), and the majority of these capillaries remained non-flowing for the duration of imaging
(Figure 8d, e, red lines). Within 30 minutes post-onset, we observed deterioration of the BBB,
which manifested as extravasation of the fluorescent i.v. dye (Figure 8c, d, f). We noted that
leakage was heightened in small regions along the capillary, spanning 10 to 40 μm in length, despite
loss of flow through entire capillary segments that were typically 50 to 100 μm in length. Leakage
only occurred in capillaries experiencing complete cessation of blood flow (0% of 56 flowing
segments, and 60% of 39 non-flowing segments within the same imaged tissue volume). This
suggested that localized BBB leakage was an effect of capillary ischemia, rather than non-specific
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actions of phototoxicity or oxidative injury, which would have similarly affected flowing capillaries
(Figure 8d, black lines). We performed initial studies with a high molecular weight dextran (2
MDa), which diffused more slowly and allowed the initial sites of extravasation to be better

Figure 8. Induction of capillary ischemia during two-photon imaging. a, Schematic demonstrating the
imaged tissue volume. Focal photothrombotic irradiations were directed at the capillary bed to generate
restricted regions of capillary ischemia. b, Experimental time course for imaging of vascular leakage after
photothrombosis. c, Progression of capillary intravenous dye (FITC-dextran) leakage following
photothrombosis. The focal point of the green photothrombosis laser is marked with a yellow circle. White
arrows correspond to leakage sites. d, Schematized vascular map from c to show capillaries with red blood
cell flow (black) or without flow (red). Regions of intravenous dye leakage are shown in green. e, Mean
number of nonflowing capillary segments over the experimental time course. The zero time point is collected
immediately following occlusion. f, Mean number of leakage sites occurring within the imaging field over
the experimental time course. N_18 occlusion sites over 10 mice for both e and f. The number of capillary
segments or leakage sites is counted within the sampled tissue volume, 0.007mm3. Data are shown as the
mean_SEM.
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discerned (Chen, B. et al., 2009). However, subsequent studies showed similar leakage with a 70
kDa Texas red-dextran, indicating extravasation of smaller blood components as well.

2.3.2. Plasma leakage emerges preferentially at pericyte somata.
We examined the spatial relationship between localized capillary leakage and the position
of pericyte somata, which were visible in a second channel when imaging PDGFRβ-tdTomato mice
(Figure 7). The leakage sites typically possessed an intensely fluorescent focus surrounded by a
more diffuse cloud of fluorescence. We observed leakage sites closely associated with pericyte
somata as well as sites away from pericyte somata. These events were categorized as pericyte
specific or non-pericyte specific, based on the localization of the somata to the focus of the plasma
leakage plume (see methods). To confirm that our visual inspection truly captured this dichotomy,
we used a series of adjacent regions of interests (ROIs) strung along a subset of capillaries to
measure the volume of extravasated i.v. dye relative to the pericyte soma (Figure 7a,b). This data
confirmed that, in many cases, the ROI with greatest dye extravasation volume overlapped directly
with the location of the pericyte soma (Figure 7a-c). At leakage sites not associated with pericyte
somata, the dye extravasation profile was similar to pericyte soma leakage sites (Figure 7d-f).
We next quantified the relative abundance of leakage sites occurring at pericyte soma
versus non-soma locations (Figure 9). Over a 3 hour post-occlusion period, pericyte soma leakage
sites developed at ~3-times the rate of non-soma leakage sites, i.e. ~ 80% of all leakage sites
observed (Figure 9a,c). A similar effect was observed in another pericyte-labeled mouse line,
NG2-tdTomato (Figure 9b,d). Using cortical vascular reconstructions from PDGFRβ-tdTomato
mice (Hartmann, D.A et al., 2015), we determined that only 7.1 ± 0.4% (mean ± s.d.) of the total
capillary length was in contact with pericyte somata, while the remainder was covered by the
extensive pericyte processes (105 mm of total capillary length examined from n = 3 mice). Thus, a
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disproportionate number of leakage sites were occurring in a restricted fraction of the capillary bed
where pericyte somata were located.

Figure 9. Capillary leakage sites occur preferentially at pericyte somata. a, b, Representative highresolution examples of capillary leakage occurring at the pericyte soma. Leakage is observed with both
PDGFR_-tdTomato (a) and NG2-tdTomato (b) mice. The locations of pericyte somata are marked with red
arrows, while the first observation of local intravenous dye leakage is marked with white arrows. Images are
maximal projections over_15_m of tissue. c, d, Mean number of leakage sites occurring at the pericyte soma,
versus regions with no pericyte soma, plotted as a function of time. p_0.001 (main effect),
F(2.87,34.45)_18.553 for PDGFR_-tdTomato (n_7 occlusion sites over four mice), and p_0.001 (main
effect), F(2.35,37.66)_9.343 for NG2-tdTomato (n_11 occlusion sites over six mice); two-way ANOVA
with repeated-measures with Greenehouse–Geisser correction. Data are shown as the mean_SEM.

2.3.3. Pericyte soma-specific capillary leakage is dependent on gelatinase activity.
To determine if MMP activity was involved in capillary leakage at pericyte somata, we
administered small molecule inhibitors of MMPs intraperitoneally 30 minutes prior to
photothrombosis. We used GM6001 (Lee, S. R. et al., 2006) to block MMPs broadly or SB-3CT
(Gu, Z. et al., 2005) to inhibit the gelatinase isoforms, MMP-9 and MMP-2 (Figure 10). Both
inhibitors effectively attenuated the formation of leakage events at pericyte somata compared to
untreated controls (Figure 10a-c). MMP inhibitors did not significantly affect the number of
leakage sites occurring in the absence of a pericyte soma (Figure 10d). We also treated animals
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with vehicle only (DMSO, PBS and PEG), to control for the effects of DMSO, which was necessary
to dissolve the inhibitors. Dimethyl-sulfoxide has been reported to exacerbate BBB leakage
(Broadwell, R. D. et al., 1982), and consistent with this, the rate at which leakage events formed
increased slightly or trended toward increase at both pericyte soma and non-soma locations
compared to untreated controls (Figure 10c,d). Nevertheless, the MMP inhibitors were able to
overcome leakage at pericyte somata induced by both ischemia and the vehicle. Critically, MMP
inhibitors had no impact on the blockade of capillary flow by photothrombosis (Figure 10e).

2.3.4. In vivo high-resolution two-photon imaging of gelatinase activity.
To better understand the relationship between gelatinase activity and pericyte-specific
leakage, we next performed in vivo gelatin zymography in PDGFRβ-tdTomato mice using twophoton microscopy (Bell, R.D. et al., 2012; Bozdagi, O. et al., 2007; Garcia-Alloza, M. et al.,
2009). To observe FITC-gelatin activation in the capillary bed, we pressure injected a FITC-gelatin
probe into the cortex prior to sealing the cranial window (Figure 11a,b). On proteolytic cleavage
by either MMP-2 or MMP-9, the FITC-gelatin fragments increase in fluorescence, allowing the
detection of gelatinase activity with high spatiotemporal precision. Consistent with its sensitivity
to gelatinase activity in vivo, basal FITC-gelatin fluorescence throughout the imaging field was
reduced by 43 ± 9% in MMP-9 knockout mice, compared to C57BL/6 controls (n = 3 for both
MMP-9 knockout and C57BL/6 groups. p < 0.05, t-test).
We next examined FITC-gelatin fluorescence changes at the cellular level in PDGFRβtdTomato mice. Since FITC-gelatin cleavage was irreversible, we could observe an accumulation
of fluorescence at cell bodies with heightened MMP-2/9 activity. FITC-gelatin labeled cell bodies
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Figure 10. Systemic administration of MMP inhibitors attenuates leakage occurring at pericyte somata.a, b,
Representative examples of capillaries before and 90 min following photothrombosis with various treatment
groups. These studies were performed with NG2-tdTomato mice. Mice were intraperitoneally injected with a
broad-spectrum MMP inhibitor, GM6001, or anMMP2/9-specific inhibitor, SB-3CT, and compared with vehicletreated or nontreated controls. Data for the control group are equivalent to those of the NG2-tdTomato data shown
in Figure 3d. The locations of pericyte somata are marked with red arrows. The first observation of leakage sites is
marked with a white arrow. c, Summary for rate of leakage site formation in various treatment groups occurring at
pericyte somata. p_0.001 (main effect); ***p_0.001 (vehicle vs GM6001); ***p_0.001 (vehicle vs SB-3CT);
**p_0.01 (control vs GM6001); ***p_0.001 (control vs SB-3CT); p_0.22 (vehicle vs control); p_0.67 (GM6001 vs
SB-3CT); F(7,68)_12.993; one-way ANOVA with Tukey’s HSD post hoc test (n_7 occlusion sites over four mice
for vehicle; n_11 occlusion sites over six mice for control; n_7 occlusion sites over five mice for GM6001; and
n_12 occlusion sites over four mice for SB-3CT). Data are shown as the mean_SEM.d, Summary for the rate of
leakage events occurring at nonpericyte soma locations. p_0.001 (main effect); **p_0.01 (vehicle vs GM6001);
*p_0.05 (vehicle vs SB-3CT); p_1.00 (control vs GM6001); p_1.00 (control vs SB-3CT); *p_0.05 (vehicle vs
control); p_0.41 (GM6001 vs SB-3CT); F(7,68)_12.993; one-way ANOVA with Tukey’s HSD post hoc test. Data
are shown as the mean_SEM. e, The average number of nonflowing capillary segments generated by
photothrombosis, examined at 120 min postocclusion, was not different between treatment groups. p_0.61; oneway ANOVA. Data are shown as the mean_SEM.

were categorized as either pericytes (tdTomato-positive) or non-pericytes (tdTomato-negative). We
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present these results by first describing the evolution of FITC-gelatin activation following control
sham irradiation (Figure 11) and photothrombotically induced capillary ischemia (Figure 12). We
then describe the relationship between FITC-gelatin activation and plasma leakage occurring at
pericyte somata (Figure 13) and away from pericyte somata (Figure 14).

Figure 11. In vivo imaging of FITC-gelatin activation following sham irradiation. a, Experimental time
course for intracortical injection of FITC-gelatin and in vivo imaging. b, Schematic showing the pressure
injection of FITC-gelatin into cortex, and subsequent imaging. Sham irradiation involves exposure to focused
green laser light, but no intravenous injection of Rose Bengal. c, d, Representative two-photon images
demonstrating pericyte location (c) and the change in FITC-gelatin fluorescence (d) following sham irradiation.
White arrowheads show examples of bright puncta that may correspond to synaptic gelatinase activity. The red
circle indicates an FITC-gelatin-positive pericyte soma, which colocalizes with tdTomato signal. The green
arrows indicate the location of FITC-gelatin-positive cells that were not colocalized with tdTomato
(nonpericytes). Images are maximal projections over_15_mof tissue. e, Magnified view of the FITC-gelatinpositive pericyte soma (red circle in d, 60 min). f, Magnified view of a FITC-gelatin-positive nonpericyte (top
green arrow in d, 60 min). g, Mean number of FITC-gelatin-positive pericytes (red) and nonpericyte cells
(green) before and 60 min after sham irradiation. Paired-samples t tests. **p_0.01 (n_6 occlusion sites over
four mice). Data are shown as the mean_SEM.

Prior to sham irradiation, the cortex emitted a homogenous fluorescence from the neuropil.
Scattered throughout the neuropil were brightly-labeled puncta (1-2 μm in diameter) that likely
represented remodeling synapses or dendrites, as previously reported (Bozdagi, O. et al., 2007)
(Figure 11c,d, white arrowheads). Over a period of 60 minutes after sham irradiation, we
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observed a modest but significant increase in FITC-gelatin labeled pericytes (Figure 11d,e; red
circle; Figure 11g). We further detected an increase in the number of non-pericyte cells in the
neuropil, which possessed glial-like morphology (Figure 11d,f; green arrow; Figure 11g).
Following the induction of capillary ischemia, we observed a robust increase in FITCgelatin activation (Figure 12a). The number of both FITC-gelatin labeled pericytes and nonpericyte cells was three-fold greater than that seen following sham irradiation, over a similar 60
minute period of imaging (Figure 12b). SB-3CT is a potent blocker of both MMP-2 and MMP-9.
To better understand the isoform specific contributions in our model, we examined the effect of an
MMP-9 specific inhibitor (C27H33N3O5S) or an MMP-2 specific inhibitor (Oleoyl-Nhydroxylamide). These inhibitors were co-injected into the brain along with FITC-gelatin since
their ability to pass the BBB was unclear. When the MMP-9 inhibitor was co-injected, the number
of labeled pericyte somata was significantly reduced (Figure 12c). In contrast, co-injection of the
MMP-2 inhibitor had no effect on labeled pericyte somata. Non-pericyte cells exhibited the reverse
outcome with inhibitors, where the number of labeled cells was reduced with the MMP-2 inhibitor,
but not with the MMP-9 inhibitor (Figure 12d).

2.3.5. Preferential MMP-9 activity and capillary leakage at pericyte somata.
We next examined how these changes in gelatinase activity related to capillary leakage.
Capillary flow and leakage in these experiments were observed with an i.v. injected 70 kDa Texas
red-dextran dye, which was imaged concurrent with FITC-gelatin at 800 nm two-photon excitation
using two-channel detection. TdTomato-positive pericytes, which shared a similar emission
spectrum as Texas red-dextran, were distinguished by imaging at a longer two-photon excitation
wavelength of 975 nm at the beginning of each experiment.
Consistent with increased MMP-9 activity causing capillary wall damage, leakage cooccurred with FITC-gelatin activation at pericyte somata (Figure 13). When multiple pericytes
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Figure 12. In vivo imaging of FITC-gelatin reveals rapid MMP-9 activation during capillary ischemia. a,
Location of tdTomato-positive pericytes visualized in a PDGFR_-tdTomato mouse with representative
examples of FITC-gelatin activation at various time points following photothrombotic occlusion of capillaries.
Red circles indicate FITC-gelatin-positive pericyte somata, while green arrows indicate the location of FITCgelatin-positive cells that were not colocalized with tdTomato (nonpericytes). b, Mean number of FITC-gelatinpositive pericytes (red) and nonpericyte cells (green) before and 60 min after photothrombosis. Paired-samples
t tests. ***p _ 0.001 (n _ 9 occlusion sites over four mice). c, Mean number of FITC-gelatin-positive pericyte
soma over the experimental time course. p_0.001 (main effect). *p_0.05, **p_0.01, compared with the NoInhibitor group; two-way ANOVA with repeated measures and Greenehouse–Geisser correction. Significance
between individual time points was determined by Bonferroni post hoc analysis. MMP-9i, n_6 occlusion sites
over three mice; MMP-2i, n_6 occlusion sites over three mice; Control, n_9 occlusion sites over 4 mice. d,
Mean number of FITC-gelatin-positive nonpericyte cells over the experimental time course. p_0.001 (main
effect). *p_0.05, **p_0.01, compared with the No Inhibitor group; two-way ANOVA with repeated measures
and Greenehouse–Geisser correction.Significance between individual time points was determined by
Bonferroni post hoc analysis. Data are shown as the mean_SEM.

were visible within a single imaging field, FITC-gelatin activation concentrated around pericyte
somata, while intervening regions covered by thin pericyte processes remained comparatively
unlabeled (Figure 13a,b). Upon closer inspection, a clear co-localization could be observed
between pericyte somata and FITC-gelatin activation within the first 30 minutes of ischemia
(Figure 13c-e). In some cases, the proximal processes emerging from the pericyte soma were
labeled (white arrowheads; Figure 13c; 10 minutes, and Figure 13d; 30 minutes). In most cases,
FITC-gelatin activation at the pericyte soma was followed by extravasation of the i.v. dye (white
arrow; Figure 13c; 60 minutes, and Figure 13e; 30 minutes), as was seen in earlier experiments.
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Within 60 minutes post-occlusion, gelatinolytic activity would then spread outward from the
pericyte soma into the parenchyma or intraluminal space, possibly due to release of active MMP-

Figure 13. In vivo imaging of FITC-gelatin reveals rapid MMP-9 activation at pericyte somata before
capillary leakage. a, b, Representative wide-field images showing the location of pericyte somata (white
circles, tdTomato), capillaries (intravenous dye) and FITC-gelatin activation before (a) and 30 min following
(b) photothrombosis. c– e, Representative high-magnification images showing the precise location of pericyte
soma (white, circles) on capillaries (red) and FITC-gelatin activation (green) over the experimental time course.
White arrowheads refer to FITC-gelatin activation on proximal processes of pericytes. White arrows indicate
the first observation of capillary leakage. The example in d shows FITC-gelatin activation at the pericyte soma,
but no obvious leakage over the imaging time course. f, Mean number of leakage sites occurring at pericyte
somata with and without coinjection of isoform-specific inhibitors of MMP-9 (MMP-9i) and MMP-2 (MMP2i). **p_0.01; one-way ANOVA. MMP-9i, n_6 occlusion sites over four mice; MMP-2i, n_6 occlusion sites
over three mice; Control, n_9 occlusion sites over four mice. Data are shown as the mean_SEM.
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9. Consistent with reduction of FITC-gelatin labeled pericytes (Figure 12c), co-injection of the
MMP-9 inhibitor, but not MMP-2 inhibitor, significantly reduced the number of leakage sites
occurring at pericyte somata (Figure 13f). Collectively, these data indicate that pericyte somata are
a locus of rapid, MMP-9 dependent capillary wall damage during ischemia.
FITC-gelatin activation was observed at all leakage sites examined, regardless of the
presence of a pericyte soma (100% of 61 leakage sites over 5 mice). FITC-gelatin activation at sites
without a pericyte soma involved either capillary contact by the processes of a FITC-gelatin labeled
glial-like cell (Figure 14a, white arrowhead), or localized perivascular FITC-gelatin activation
(Figure 14b). However, the number of non-pericyte leakage sites was not reduced by MMP-9 or
MMP-2 inhibitors (Figure 14c). This finding indicates that there are multiple cellular sources of
gelatinase activity induced during capillary ischemia, and that these varied sources may respond to
different inhibitor concentrations than that effective for mitigating pericyte-specific MMP-9
activity and leakage.

Figure 14. Ischemia-induced FITC-gelatin activation and capillary leakage occurring in regions without
a pericyte soma. a, b, Representative high-magnification images showing the location of FITC-gelatin
activation over the experimental time course. Pericytes, where present within the image field, are indicated by
tdTomato labeling (white). a, A parenchymal cell with glial morphology contacting the leaking capillary (white
arrowhead). b, A perivascular region of FITC-gelatin activation distant from the pericyte soma. c, Mean
number of leakage sites occurring in the absence of pericyte somata with and without coinjection of isoformspecific inhibitors of MMP-9 and MMP-2. No significance was found with one-way ANOVA. MMP-9i, n_6
occlusion sites over three mice; MMP-2i, n_6 occlusion sites over three mice; Control, n_9 occlusion sites over
four mice. Data are shown as the mean_SEM.
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2.4. Discussion
A major goal in stroke research is to understand and control processes that lead to BBB
disruption (Sandoval, K. E. & Witt, K. A., 2008). In this study, we have used an in vivo two-photon
imaging approach with a novel capillary ischemia model to demonstrate that pericyte somata are a
previously undefined locus of heightened BBB disruption. We find that FITC-gelatin activation
precedes leakage at pericyte somata, and can be blocked by MMP-9 inhibition but not MMP-2
inhibition (Figure 15a-c). Further, leakage occurs only after complete cessation of flow in the
adjoining capillary (Figure 15d). Our results indicate that pericyte somata are found along only
7% of the cortical capillary network, yet account for ~80% of the sites for localized plasma leakage.
Although pericyte-specific leakage occurs within a small fraction of the total capillary network,

Figure 15. Summary diagram of BBB disruption at pericyte somata. a– c, Summary data showing the
mean number of leakage sites occurring at pericyte somata (red line) and the number of FITC-gelatin-positive
pericyte somata over 1 h of imaging. Coinjection of anMMP-9inhibitor reduces both FITC-gelatin activation
and capillary leakage at pericyte somata, while anMMP-2inhibitor has comparatively no effect. Data are shown
as the mean_SEM. d, Nonflowing capillaries (no red blood cells) in the imaged region will experience BBB
disruption at pericyte somata, while closely neighboring capillaries with flow remain intact. Rapid activation
and release of MMP-9 at the pericyte soma damages the capillary wall in a focal manner.
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blood-borne molecules that enter the brain through this route may diffuse and affect brain function
distant to the site of leakage. Developing strategies to reduce capillary leakage at pericyte somata
may help to protect the brain during stroke, and possibly other neurological diseases involving
capillary flow impairment such as traumatic brain injury (Østergaard, L. et al., 2014; Sword, J. et
al., 2013) and dementia (Farkas, E. & Luiten, P. G. M., 2001; Østergaard, L. et al., 2016).

2.4.1. Pericyte vulnerability to ischemia
These findings support and build on our current understanding of the acute pericyte
response to ischemia/injury. Recent studies by Hall and Attwell revealed a specific vulnerability of
pericytes during simulated ischemia in brain slices and in vivo following middle cerebral artery
occlusion (Hall, C. N. et al., 2014). While loss of pericyte viability was suspected to cause BBB
leakage, the underlying mechanism of vascular damage, timing of injury processes, and relation to
capillary flow remained unclear. We show that one mechanism is the rapid mobilization of MMP9 from pericyte somata (within tens of minutes) during capillary ischemia. We suggest that
pericytes themselves are the source of MMP-9, based on the marked co-localization between FITCgelatin and tdTomato-positive pericytes during early stages of MMP-9 activation (Figure 13).
Since the soma is the largest subcellular compartment of the pericyte, and likely harbors the most
MMP-9 protein, it is reasonable to expect the most potent FITC-gelatin activation and leakage at
the soma. Other studies also support the idea that pericytes are sources of MMP-9. In culture,
human pericytes induce MMP-9 activity, but not MMP-2 (Takahashi, Y. et al., 2014b). Cultured
rat pericytes release more MMP-9 than either endothelial cells or astrocytes following thrombin
treatment (Machida, T. et al., 2015). Further, cerebral pericytes in Apoe-deficient and APOE4
transgenic mice express higher MMP-9 levels through a cyclophilin (CypA)-nuclear factor κB
pathway (Bell, R.D. et al., 2012). Given the rapid nature of FITC-gelatin unquenching in the
current in vivo study, it is conceivable that pericytes activate a pool of proMMP-9 zymogens

57
through a non-transcriptional route such as S-nitrosylation (Gu, Z. et al., 2005). If so, pre-existing
co-morbidities that promote MMP-9 expression in pericytes, could lead to more severe responses
during ischemic injury.

2.4.2. Pericyte involvement in transcytosis and paracellular leakage
Recent studies have proposed a step-wise process for BBB disruption during ischemia,
where leakage by endothelial transcytosis (transcellular leakage) precedes degradation of the tight
junctions (paracellular leakage)(Knowland, D. et al., 2014). We postulate that leakage at pericyte
somata is an intermediate step between these classic forms of BBB disruption. The concentrated
activation of MMP-9 at the pericyte somata likely leads to degradation of the underlying tight
junction complexes (Yang, Y. et al., 2007), while the intervening regions of the capillary bed
maintain tight junction integrity but exhibit increased endothelial caveolae (Krueger, M. et al.,
2013; Nahirney, P. C. et al., 2015). If so, there may be conditions under which both transcellular
and paracellular leakage routes co-exist along the same capillary segments. In a typical middle
cerebral artery stroke, pericyte soma leakage might occur within, and just beyond, the ischemic
core, where some capillaries are expected to be completely blocked (Srinivasan, V. J. et al., 2013).
Indeed, similar plumes of leakage have been observed with electron microscopy during middle
cerebral artery stroke (Ohtake, M. et al., 2004). Unexpectedly, past imaging studies have shown
that leaked blood components do not significantly affect neuron structure or function in the acute
time-frame of hours (Cianchetti, F. A. et al., 2013; Zhang, S. & Murphy, T. H., 2007). However,
the impact of the delayed inflammatory responses to capillary leakage, which occur over days to
weeks following injury, remains to be examined.

2.4.3. Pericytes and local MMP-9 activity
We showed overlap between FITC-gelatin probe activation and pericyte somata, providing
evidence that pericytes may be a source of MMP-9 in vivo (Figure 13). However, we have not
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modulated pericytes in a cell-specific manner to confirm this idea. The barrier to such an
experiment is that manipulation of pericyte signaling or migration would itself compromise the
BBB (Armulik, A. et al., 2010; Bell, R.D. et al., 2010; Daneman, R. et al., 2010b), altering basal
MMP-9 expression/activity profiles in pericytes and other cell types. Thus, it remains possible that
pericytes interact closely with neighboring endothelial cells (Zozulya, A. et al., 2008) or leukocytes
(Stark, K. et al., 2013) to activate MMP-9 during ischemia. While numerous cellular sources of
MMP-9 have been demonstrated in stroke models, including neutrophils, microglia, astrocytes or
endothelial cells (del Zoppo, G. J. et al., 2012; Gidday, J.M. et al., 2005; Justicia, C. et al., 2003;
Rosell, A. et al., 2006; Zhao, B-Q et al., 2006), the key finding of the current study is the striking
enrichment of MMP-9 activity at pericyte somata and the speed of its activation, warranting further
investigation of this phenomenon in other models of stroke and cerebrovascular disease. Future
studies are needed to better understand the mechanisms that control rapid MMP-9 activation at
pericyte somata, and how pericytes contribute to overall BBB disruption in different disease states.
Further, it will also be important to determine whether pericytes die (Hall, C. N. et al., 2014) or use
MMP-9 to actively migrate from the endothelium (Dore-Duffy, P. et al., 2000), as their long-term
fate may also be important for tissue revascularization and recovery.

59

Chapter 3: Dose dependent effect of L-NIL on the activation of matrix metalloproteinase
2/9 during ischemia in vivo.

Robert Underly1 & Andy Shih1, 2

1

Department of Neurosciences and 2Center for Biomedical Imaging, Medical University of South
Carolina, Charleston, SC, USA

60
3.1 Introduction
Cerebral vascular homeostasis is achieved through biochemical signaling of neurovascular
cells and maintenance of the blood-brain barrier (BBB). Pericytes have been shown to be an integral
component of microvascular health. (Costa, M. A. et al., 2018; Hall, C. N. et al., 2014; O'Farrell,
F. M. et al., 2017). Pericytes function through continuous signaling with the endothelium which
allows for vascular stability (Berthiaume, A.-A. et al., 2018; von Tell, D. et al., 2006), normal tight
junction formation (Armulik, Annika et al., 2010), and microvascular maturation (Armulik, A. et
al., 2011; Armulik, Annika et al., 2010; Greenberg, J. I. et al., 2008). When pericytes are lost
through genetic deletion, basement membrane thickening, vascular leakage, and dysregulation of
endothelial signaling occurs (Lindahl, Per et al., 1997). Pericytes have also been shown to be
uniquely sensitive to ischemia, dying prior to other cells of the neurovascular unit. Previously we
have also shown that following targeted photothrombosis, capillary leakage occurs preferentially
at pericytes somata. As means of determining the biochemical steps leading to BBB breakdown
during this process, we were also able to demonstrate that this process was dependent on matrix
metalloproteinase 9 (MMP 9).
A wealth of information exists demonstrating that early MMP-9 activation is a fundamental
component of cerebral ischemia in numerous models (Amaro, S. et al., 2009; Gasche, Y. et al.,
1999; Xing, C. et al., 2014b), and it serves as a biomarker for complications in human stroke.
During cerebral ischemia activation of proteolytic enzymes can lead to BBB permeability, and
pericytes have been implicated in the production of MMP 9 during neuroinflammatory (Machida,
T. et al., 2015) and ischemic conditions (Underly, R. G. et al., 2017). In our previous work there
was colocalization between pericyte somata and MMP activity at regions of BBB breakdown. This
activation occurred much faster than previous reported (within tens of minutes) making it important
to understand the mechanisms by which this activation could occur. By delineating the mechanisms
that underlie pericyte proteolytic responses to ischemic conditions, potential targets for therapeutic
intervention could be found. To pursue this goal it is important to understand the time course over
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which activation of these enzymatic responses occur, and which molecular targets lead to their
activation. Here we look to explore nitric oxide as a potential contributor to rapid proteolytic
responses to microvascular ischemia.
Nitric oxide (NO) is a diffusible signaling molecule that promotes vascular relaxation
(Alderton, W. K. et al., 2001; Bredt, D. S. & Snyder, S. H., 1990), synaptic plasticity (Böhme, G.
A. et al., 1993; Böhme, G. A. et al., 1991), and functions as a signaling molecule in synaptic
transmission (Sagi, Y. et al., 2014), making it an integral molecule in the regulation and
maintenance of vascular health and homeostasis. Nitric oxide is produced through the oxidation of
L-arginine by three isoforms of nitric oxide synthase (NOS) which include neuronal NOS (nNOS),
endothelial NOS (eNOS), and inducible NOS (iNOS). Two isoforms, nNOS and eNOS, are
considered constitutively active in resting cells and also calcium dependent, while iNOS is
activated through stimulation by pro-inflammatory cytokines and is calcium independent
(Alderton, W. K. et al., 2001; Bredt, D. S. & Snyder, S. H., 1990). Each of these isoforms have
different implications during ischemia, and their inhibition has been shown to differentially impact
outcomes of ischemic injury (Willmot, M. et al., 2005). Substantial focus has been put on outcomes
of NOS inhibition at time points beyond one hour, but limited evidence exists elucidating potential
rapid mechanisms by which NO acts during ischemia. Here we look to determine if NOS inhibition
is sufficient to reduce matrix metalloproteinase activity and vascular leakage during capillary
ischemia in vivo.

3.2 Methods
3.2.1 Mice
Tdtomato reporter mice (Ai14) on a C57/Bl6 background were purchased from Jackson
Labs (stock no. 007914). These mice were crossed with PDGFRβ-Cre mice to achieve transgene
expression in pericytes. Mice were maintained in standard cages on a 12 hour light-dark cycle, and
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housed 5 or less per cage. Both male and female mice were used, and all mice used were between
2 to 5 months of age.

3.2.2 Surgery
Skull-removed, dura-intact craniotomies (Mostany, R. & Portera-Cailliau, C., 2008) were
generated over the sensorimotor cortex to achieve optical access for two-photon imaging.
Intracortical injections of DQ-gelatin and other drugs were performed (see below) when the
craniotomies were generated and animals were imaged immediately after sealing the craniotomy
with a coverslip. Anesthesia was induced with isoflurane (Patterson Veterinary) at 3% mean
alveolar concentration in 100% oxygen and maintained at 1 to 2% during surgery. Body
temperature was maintained at 37oC with a feedback-regulated heat pad. All animals were
administered buprenorphine for analgesia prior to surgery at a concentration of 0.025 mg/kg. These
procedures were approved by the Institutional Animal Care and Use Committee at the Medical
University of South Carolina.

3.2.3 In vivo two-photon microscopy
Two-photon imaging was performed with a Sutter Moveable Objective Microscope and a
Coherent Ultra II Ti:Sapphire laser source. An excitation of 800 nm was used for excitation of
FITC-gelatin and Texas red-dextran. Excitation was tuned to 975 nm to capture tdTomato
fluorescence at the start of each experiment. Green and red emission was simultaneously collected
using ET525/70m and ET605/70m filter sets, respectively (Chroma Corp.). Throughout the
duration of imaging, mice were maintained under light isoflurane (0.75%) supplied in medical air
(20-22% oxygen and 78% nitrogen, moisturized by bubbling through water; AirGas Inc.). Pulse
oximetry (MouseOx; Starr Life Sciences) was used to monitor blood oxygen saturation and heart
rate to ensure that cardiovascular function was normal during imaging.
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Procedures for blood flow imaging and analysis have been described previously (Shih, A.
Y. et al., 2012).Briefly, the blood serum was labeled by infraorbital vein injection of 0.025 mL of
Texas red-dextran (70 kDa, D-1830; Life Technologies) prepared at a concentration of 5 % (w/v)
in sterile saline. A 4-X, 0.13 NA air objective lens (UPLFLN 4X; Olympus) was used to generate
vascular maps of the entire window for navigational purposes. High-resolution imaging was
performed using a water immersion 20-X, 1.0 NA objective lens (XLUMPLFLN 20XW;
Olympus).

3.2.4 Photothrombotic occlusions
Restricted photothrombotic capillary occlusions have been previous described (Underly & Shih,
2017). Briefly, a focused green laser (1 mW, 20 μm diameter at focal plane) was applied directly
to the superficial capillary bed (avoiding pericyte somata) for 25 seconds following an infraorbital
injection of Rose Bengal (0.013 mg/kg). This led to the diffuse irradiation of a small number of
surrounding capillaries.

3.2.5 Quantification of capillary leakage sites
Image stacks collected in vivo using two-photon microscopy were rendered in 3-D using
Imaris 7.7 Software (Bitplane). Lateral sampling was 0.41 µm per pixel and axial sampling was
1 µm per pixel. Vascular leakage was quantified from 3-D renderings of the TexasRed-dextran
labeled red channel, and also confirmed in 2-dimensional images by scrolling through z-stacks with
Fiji software. This method of quantification was previous described (Underly et al., 2017; Underly
& Shih, 2017). Briefly, however, leakage events were defined as the localized permeation of
TexasRed-dextran from the intravascular space into the surrounding parenchyma. The sites of
leakage were separated into pericyte-specific and non-pericyte leakage sites based on the
localization of the pericyte soma to central portion of the intravascular dye extravasation. These
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leakage sites were counted at each time point to give a cumulative total of the number of sites
during the one hour duration of the experiment.

3.2.6 In vivo gelatin zymography
A FITC-gelatin probe (Bozdagi, O. et al., 2007)(DQ-Gelatin, D12054; Life Technologies),
diluted to a concentration of 1 mg/mL in sterile PBS, was pressure injected into the cortex using a
pulled glass pipette (10-20 µm tip diameter). The pipette tip was lowered 250 µm into the cortex
following the removal of a circular portion of skull (~2 mm) over the somatosensory area. A small
incision was made in the dura mater using a 26-gauge syringe needle tip for entry of the glass
pipette. FITC-gelatin was injected over 5 minutes using a Picospritzer (10-20 ms pulses, 5-15 psi,
0.5-2 Hz pulse frequency) until 200 nL was delivered. The injection pipette was then left in place
for 10 minutes before removal from the cortex. The craniotomy was then overlaid with 1.5%
agarose followed by a circular coverslip. The coverslip was fixed in position with dental cement
prior to two-photon imaging. Quantification of “MMP-positive” cells was previously described
(Underly et al., 2017). Cells that co-localized with pericyte somata (tdTomato) were counted as
FITC-gelatin positive pericytes. Areas of heightened FITC-fluorescence that did not co-localize
with pericyte somata, but exhibited some cellular morphology, were counted as FITC-gelatin
positive non-pericytes.

3.2.7 Nitric oxide synthase inhibition
L-NIL was prepared into stock solutions by dissolving 1mg/ml L-NIL in artificial cerebral spinal
fluid (ACSF) and then diluting into usable concentrations (3.8µM; 19µM) and combining with the
FITC-Gelatin which was then injected intracortically.
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3.2.8 Protein synthesis inhibition
Anisomycin was administered intraperitoneally at a concentration of 75mg per kg of mouse
body weight. Anisomycin was prepared by adding the minimum amount of 1M HCL required to
bring the Anisomycin into solution. Sodium hydroxide (1M) was then added to bring the solution
to a neutral pH. Saline was then added to bring the solution to the appropriate concentration
(Wanisch and Wotjak, 2008). Intraperitoneal administration of Anisomycin was done 30 minutes
prior to taking the pre-occlusion imaging stack for the experiments in which it was used. Capillary
occlusions were made ~35 minutes following Anisomycin administration.

3.2.9 Statistics
All statistical analyses were performing using SPSS software. Statistical details are
provided in the legend of each figure. Our sample size was similar to previously reported studies
using similar imaging techniques. Any corrections for sphericity that were needed were done using
Greenhouse-Geisser correction. All data sets examined contained normative values.

3.3 Results
3.3.1 Photothrombotically induced capillary ischemia and FITC-Gelatin imaging
Previously, we established a method of inducing capillary ischemia in vivo using targeted
photothrombosis within the capillary bed (Underly et al., 2017); this method is utilized here to
probe a pathway of rapid proteolytic activity following induction of ischemia in vivo (Fig. 16a).
Using a mouse line with fluorescent pericytes (PDGFRβ-Ai14), along with a 70 kDa dye
(TexasRed), we are able to visualize pericytes and the vasculature of these animals (Fig. 16d).
Through the use of a FITC-Gelatin probe, via an intracortical injection (Fig. 16a), we are able to
image proteolytic activity within a portion of cortical space (~500µm x ~500µm x 250µm) with
precise spatiotemporal resolution in vivo (Fig. 16b, d). We chose regions of interest (ROIs) with a
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cortical volume of 200µm x 200µm x 150µm to image as FITC-Gelatin could be seen throughout
this volume of tissue.

3.3.2 Plasma leakage predominately occurs at pericyte somata while MMP activity occurs at
all leakage sites
Previously we have shown that capillary leakage, following targeted photothrombosis,
occurs preferentially at pericytes somata, and that MMP-9 activity was a contributor to this leakage
(Underly et al., 2017). Here we looked to reproduce that result to explore the consistency of the
effect while also working to probe the mechanism of the activation of MMP 2/9 at these locations.
In this study we were able to reproduce our previous effect.
Regions of plasma leakage contained a bright fluorescent focus and the injected vascular
dye slowly diffused away from the border of the surrounding vasculature as well as the space
occupied by dye at previous time points of the same vascular segment (Fig. 16b). Leakage sites
occurred following cessation of flow in the associated vessel segment. Through visual inspection
we were able to count the number of leakage sites at locations containing pericyte somata and those
devoid of pericytes (Fig. 16c). These leakage sites occurred significantly more at pericyte somata
compared to regions without a pericyte present (p < .01) (Fig. 16c). Finally, all leakage sites
contained increases in FITC-Gelatin fluorescence (Fig. 16b) Upon cessation of flow, subtle regions
of FITC-Gelatin fluorescence could be seen prior to vascular leakage (Fig 16b, “FITC-Gelatin”
panel 2) within tens of minutes following photothrombosis. The leakage sites containing pericyte
somata had dramatic overlap between increases in FITC-Gelatin activity and pericyte cell bodies
(Tdtomato fluorescence) (Fig. 16b, d).

3.3.3 Pericyte leakage is attenuated with high (19µM) concentrations of L-NIL and protein
synthesis
To determine if constitutively active NOS could be partially responsible for the mechanism
leading to the rapid activation of MMP-9 in capillary leakage at pericyte somata we administered
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Figure 16. Photothrombotic occlusion and FITC-Gelatin Activation. (a) Schematic showing photothrombotic
irradiation and FITC-Gelatin loading along with the experimental time course. (b) Representative images showing the
progression of capillary leakage at pericyte somata along with the associated increase in FITC-Gelatin activity at
leakage sites. (c) Mean number of leakage sites at both pericyte and non pericyte locations (**p < .01, n = 8 occlusions).
Data shown as mean ± SEM. (d) Magnified region of microvascular leakage with corresponding pericyte soma
(identified by the white circle) and FITC-Gelatin fluorescence.

the NOS inhibitor L-NIL intracortically, and an inhibitor of protein synthesis (Anisomycin)
intraperitoneally, in conjunction with FITC-Gelatin 30 minutes prior to photothrombosis. Two
doses of L-NIL were used in these experiments; a 3.8µM dose and a 19µM dose. These doses are
expected to inhibit iNOS (3.8µM) and eNOS (19µM) potentially producing variability in the
influence of each concentration. The administration of each drug was done separately and then as
a combination treatment to determine if each contributed in different ways vascular leakage and
MMP activation.
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As hypothesized the 3.8µM dose did not impact the rapid response of proteolytic activity
(Fig. 17a, d) or vascular leakage (Fig. 17a, c). However, interesting, the higher dose significantly
reduced pericyte-specific leakage events (Fig. 17b, c) as well as matrix metalloproteinase activity
at locations of leakage (reduction by 78% of MMP active leakage sites) (Fig. 17b, d). This data
suggests that constitutively active nitric oxide synthase may be playing a role in the effect seen.
Both high dose L-NIL and Anisomycin reduced the number of leakage sites at pericyte somata
significantly (Fig. 18a, b, & d) but had no effect on leakage sites devoid of pericyte somata (Fig.
18e). The combination of the treatments had a step-wise reduction in the number of leakage sites
at pericyte somata, nearly eliminating them entirely (Fig. 18c, d). The combination treatment also
had no effect on leakage sites without a pericyte somata present (Fig. 18e). With both inhibitors
reducing leakage events at pericyte somata, and having an additive effect when used in conjunction
with each other it would suggest that both translation and post-translational modifications
mechanisms contribute to vascular leakage at pericyte locations following ischemia.

3.3.4 Matrix metalloproteinase activity at leakage locations is variably influenced by L-NIL
and Anisomycin administration
To understand the influence of MMP activity at leakage locations, FITC-Gelatin activity
was examined in the presence of no drug (Fig. 19a), high dose L-NIL (Fig. 4b), Anisomycin (Fig.
19c), or both inhibitors together (Fig. 19d). When high dose L-NIL alone was present, the
percentage of pericyte-specific leakage sites with FITC-Gelatin activation was reduced by 78%
(Fig. 19b, e) and 43% at leakage sites without a pericyte soma (Fig. 19b, f). Anisomycin reduced
the percentage of FITC-Gelatin positive pericyte-specific leakage sites by 25% (Fig. 19c, e) and
the percentage of non-pericyte leakage sites by 29% (Fig. 19c, f). When both inhibitors were
present pericyte-specific leakage sites that were FITC-Gelatin positive were completely eliminated
(Fig. 19d, e) and FITC-Gelatin positive non-pericyte leakage sites were reduced by 87% (Fig. 19d,
f). This result suggests the possibility of a post-translation modification of MMPs, via NO, that
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contributes to the activation of MMP 2/9 during capillary ischemia. The results also suggest that
the post-translational influence of NO constitutes nearly three times more to the activation of MMP
2/9 than protein synthesis alone.

Figure 18. Stepwise reduction in pericyte leakage with combination treatment. (a-c) Representative images
showing the progression of microvascular leakage following administration of 19µM L-NIL (a), Anisomycin (b), and
the combination of 19µM L-NIL/Anisomycin (c). Pericyte cell bodies are demarked by white circles. (d & e) Mean
number of leakage sites at both pericyte (d) and non pericyte (e) locations following administration of 19µM L-NIL,
Anisomycin, and the combination of 19µM L-NIL/Anisomycin. (***p < .001, **p < .01, n = 8 occlusions). Data shown
as mean ± SEM
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Figure 19. Stepwise reduction in MMP active leakage sites following combination treatment. (a-d)
Representative images showing FITC-Gelatin activation following photothrombotic occlusion in controls (a), and
following administration of 19µM L-NIL (b), Anisomycin (c), and the combination of 19µM L-NIL/Anisomycin (d).
(e & f) Percentage of total leakage sites with corresponding increases in FITC-Gelatin fluorescence for control
(100% of pericyte and 97% of non pericyte), 19µM L-NIL (22% of pericyte and 57% of non pericyte), Anisomycin
(75% of pericyte and 71% of non pericyte), and the combination of 19µM L-NIL/Anisomycin (0% of pericyte and
13% of non pericyte) at both pericyte (e) and non pericyte (f) locations.

3.4 Discussion
An important step in limiting the functional deficits associated with stroke is understanding
the mechanisms of blood-brain barrier disruption during ischemia in a temporally specific manner.
We have previously shown that pericytes are an important focal point of damage at the BBB during
ischemia in the capillary bed, and that the damage at their soma corresponds to increases in MMP
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9 activity (Underly et al., 2017). We have also shown that increases in MMP 9 activity occur in a
very rapid manner (within tens of minutes) in this form of ischemia suggesting a post-translational
modification of currently present proteins. In this study we use two photon imaging and a
photothrombotic model of capillary ischemia to explore the difference between the contributions
of protein synthesis and this rapid mechanism of vascular damage.

3.4.1 Pericyte specific reductions in BBB breakdown with NOS inhibition
We find that pharmacological inhibition of NOS, using two concentrations of L-NIL, are
sufficient to significantly reduce the number of sites of BBB breakdown. We also find that vascular
damage can be further ameliorated with an inhibitor of protein synthesis. Furthermore, we find that
BBB breakdown is reduced in a pericyte-specific manner for both inhibitors, and that when the
inhibitors are used in conjunction with each other there is a step-wise reduction in leakage events
at pericyte locations. Interesting, no reduction in non-pericyte leakage sites is seen across all
inhibitors. This could represent a floor effect in our model as the average number of non-pericyte
leakage events is around ~1.5. With occlusions being made at regions not containing a pericyte
somata, and occlusion not resolving, it would make sense that this obstruction would create a
mechanical injury from the restriction of blood flow in this region.

3.4.2 Matrix metalloproteinase activity is greatly reduced with L-NIL
We also find that 19µm L-NIL reduces the percentage of MMP active pericyte-specific
leakage sites by 78%, and the percentage of MMP active non-pericyte leakage sites by 43%. This
effect was not seen with a lower dose (3.8 µM) of L-NIL. Anisomycin was only able to reduce the
percentage of MMP active pericyte and non-pericyte specific leakage sites by 25% and 29%
respectively. This finding in conjunction with our previous work, suggests that there may be a pool
of pro-MMP 9 available prior to the initiation of the ischemic injury. Matrix metalloproteinase 9 is
thought to be inducible in nature due to its pro form being present at very low levels compared to
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MMP 2, however, both are used under normal physiological conditions. It is not known, however,
what quantity of pro-MMP 9 would be required to lead to BBB breakdown. In our work we find
that inhibition of protein synthesis prior to ischemic injury only reduces MMP activity by ~25%,
yet inhibition of a rapid mechanism of MMP 9 activation (NO) reduces MMP activity to a much
greater degree.
With the combination of both inhibitors the number of MMP active pericyte leakage sites
was reduced to zero, and only 13% of non-pericyte leakage sites were MMP positive. From this
evidence we speculate that a post-translational modification of MMP 9 is one of the important
mechanism of BBB breakdown during ischemia in this model, and that pericytes either play a role
in NO production or are important cells in pro-MMP 9 release during ischemia. This information
suggests that developing strategies to target this mechanism specifically in pericytes could be
beneficial in reducing CNS damage from disease states that involve ischemic injury.

3.4.3 Nitric oxide as a contributor to rapid MMP 9 activation
Nitric oxide also has the ability to perform rapid post-translational modifications which can result
in the broad activation of a wide variety of proteins; these processes include S-nitrosylation,
tyrosine nitration, and S-glutathionylation (Bradley, S. A. & Steinert, J. R., 2016; Martínez-Ruiz,
A. et al., 2011). S-Nitrosylation is the process by which NO reacts with cysteine thiol residues on
proteins to form an S-nitrosylated derivative of the protein. This interaction, and subsequent
production of nitrosothiols, is thought to be a similar post-translational modification to
phosphorylation and acetylation. This mechanism is controlled by the availability of reactive
cysteine residues with appropriate organization and orientation for interaction with NO. Matrix
metalloproteinases (MMPs) have this type of organization making them a potential target for Snitrosylation during pathological conditions involving rapid and robust increases in NO
bioavailability through activation of NOS. S-nitrosylation of MMP 9 has been shown to play a
role in neuronal cell death (Gu et al., 2002) and to be a mechanism of MMP 9 activation in a
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variety of circumstances (Radomski et al., 1998; Mayers et al., 2001). This data provides novel
insight into the role of NO and its interactions with MMPs in vascular dysfunction and BBB
degeneration during acute ischemia. However, it is important to understand the limitations of this
work. Nakamura and Lipton (2016) provided insight into the work necessary to delineate the
specific influence of S-Nitrosylation of proteins, and that novel approaches are necessary to
reduce artifact in future studies. Here we hope to provide a bases for the need to explore the
potential importance of S-nitrosylation of MMPs during diseases involving microvascular
ischemia. Understanding the specific mechanism by which NO and MMPs interact during
ischemia could provide much needed targets for therapeutic intervention during diseases
involving microvascular ischemia.

Chapter 4: General Discussion
Stroke and neurodegenerative disease have a number of similar comorbidities and
modifiable risk factors including cardiovascular disease (Luchsinger, J. A. & Mayeux, R., 2004;
Newman, A. B. et al., 2005), diabetes (Luchsinger, J. A. et al., 2001), hypertension (Kivipelto, M.
et al., 2001) and previous ischemic incidents (Honig, L. S. et al., 2003). They also share age and
polymorphisms in apolipoprotein (APOE) as non-modifiable risk factors (Bullido, M. J. et al.,
1998; Pedro-Botet, J. et al., 1992; Tzourio, C. et al., 2008). Each of the pathologies listed have
been shown to involve elevated MMP 9 as part of its pathogenesis (Blankenberg, S. et al., 2003;
Jacqueminet, S. et al., 2006; Wallace, S. et al., 2005), and polymorphisms in APOE are associated
with pericyte loss and MMP 9 activation (Bell, R. D. et al., 2012; Halliday, M. R. et al., 2016).
Several modifiable risk factor also include a corresponding dysregulation of some NOS isoform
leading to elevated NO (Förstermann, U. & Münzel, T., 2006) or dramatic reductions in NO
(Huang, P. L. et al., 1995; Lin, K. Y. et al., 2002). Our findings add another element to this puzzle
suggesting that microvascular ischemia can result in rapid NO mediated gelatinase activation and
BBB breakdown. Importantly, this damage is localized to regions containing pericyte somata
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suggesting an important role of this cell in microvascular ischemia. We have therefore identified
NO as a rapid signaling molecule that contributes to the pathological activation of MMP 9 at
pericyte somata in a variety of prolonged disease states (i.e. those with microvascular ischemia as
a component) through modeling of microvascular ischemia. As a means of understanding these
findings in a broader context I will discuss the modeling of microvascular ischemia, localized
pericyte-specific BBB damage, pericytes as a potential source of MMP 9, and anticipated next
steps.

4.1 Modeling microvascular ischemia
We have been able to create a reproducible model of constrained capillary ischemia in
order to better understand the dynamic changes occurring during this pathological process in vivo
(Appendix 1). Microvascular ischemia is a common pathological component of a number of
neurological diseases, and a feature or consequence of their comorbidities. Alzheimer’s disease,
stroke, and vascular dementia all include microvascular ischemia as a component of their
pathogenesis. In stroke, the extent of capillary occlusion has been shown to predict prognosis of
patients with more extensive capillary ischemia resulting in worsened prognosis
(Mundiyanapurath, S. et al., 2016). In Alzheimer’s disease (AD), microvascular ischemia is
associated with reductions in blood flow leading to the aggregation of amyloid-β in perivascular
space, in a process referred to as cerebral amyloid angiopathy (CAA) (Weller, R. O. et al., 2008).
Finally, in vascular dementia (VaD) prolonged capillary occlusions have been linked to the
progression of cognitive impairment (Brown, W. R. et al., 2007). With microvascular ischemia
being so intimately linked to various disease states it has become necessary to understand the
spatiotemporal dynamics of its progression in these various disorders.
As mentioned above, the disability associated with stroke correlates with the extent of
capillary occlusion. The pathophysiology of ischemia is a reflection of specific reductions in
normal cerebral vascular blood flow (CBF). The resulting impact on tissue is dependent on the
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duration and severity of the reductions in CBF (Astrup, J. et al., 1981; Astrup, J. et al., 1977). In
stroke, the region of most severe blood flow reduction is referred to as the ischemic core while
regions with less severe reductions in CBF represent the ischemic penumbra (Sharp, F. R. et al.,
2007). This is an important concept in stroke research as variability in blood flow reductions
could represent difference in the potential to rescue tissue from damage. The exact nature of the
penumbral region isn’t fully understand making it necessary to devise models that represent
pathological features of penumbral pathophysiology. With our model we are able to occlude a
small fraction of capillaries which may replicate regions of blocked capillary flow in the
penumbra, potentially allowing us to gain insight into this facet of stroke.
Here we have taken steps toward understanding how an occlusion of a single branch
point within the capillary bed can impact the surrounding microvasculature, but we have not
applied this methodology to animal models of disease. Of particular interest are animal models of
Alzheimer’s disease. In AD, capillary flow reductions and stalls in the capillary bed have been
demonstrated in humans and animals models of this disease at greater levels compared to controls
(Brown, W. R. & Thore, C. R., 2011). This form of pathology has also been loosely linked to
CAA. A number of AD animal models exist, but APP/PS1 mice are very typical in this field.
These animals start to demonstrate significant reductions in blood flow as early as 12 weeks of
age, and these reductions are associated with reductions in the rate of red blood cell movement. It
is, however, currently unknown how this process leads to CAA or how it is linked to increases in
susceptibility to the pathological hallmarks of AD. With the model presented in this work it may
be possible to initiate pathology in these animals prior to the typical onset of disease. Through
constrained capillary occlusions it would be possible to initiate microvascular ischemia and then
track localized changes in amyloid aggregation in a spatiotemporally dynamic fashion. It would
then also be possible to attempt to understand how multiple insults could impact the surrounding
neurons, and if there is a ischemic threshold that must be met to produce amyloid plaque
formation. Finally, it would also be possible to gain an understanding of the response, and
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resulting contribution, of cell-specific proteolytic activity leading to plaque and tangle formation;
the temporal dynamics of which are still in question.

4.2 Localized, pericyte-specific blood-brain barrier damage
We have been able to demonstrate that pericytes are a locus of damage following
microvascular ischemia, adding to a body of evidence suggesting that these cells are highly
susceptible to ischemic damage (Hall, C. N. et al., 2014; Yemisci, M. et al., 2009). Pericytes have
long been considered an important component of the blood-brain barrier, but the breadth of their
function has only recently begun to unfold. Their unique position within perivascular space,
morphological extension along the vascular network, and direct interactions with the endothelium
has been shown to make pericytes vital components of BBB integrity, stability, and formation
(Armulik, A. et al., 2005; Armulik, A. et al., 2010). As novel insights into pericyte function and
methods for their visualization have been expanded, it has been possible to understand the
significance of pericyte dysfunction in a variety of pathological conditions (Berthiaume, A.-A. et
al., 2018; Dalkara, T. et al., 2011; Hall, C. N. et al., 2014; Underly, R. G. et al., 2017). Numerous
disorders with microvascular ischemia as a component of their pathogenesis seem to also be
related to dysregulated pericytes (Girouard, H. & Iadecola, C., 2006) which could contribute to
the initiation of Alzheimer’s disease and the progression of stroke. Partial genetic removal of
pericytes also seems to produce pathological symptoms that replicate components of
neurodegenerative diseases (Bell, R. D. et al., 2010; Sagare, A. P. et al., 2013).
Cerebral amyloid angiopathy has long been considered an important age-related feature
leading to the progression of Alzheimer’s disease through the exacerbation of amyloid-β load in
the CNS leading to further plaque formation (Zlokovic, Berislav V, 2005). Cerebral amyloid
angiopathy involves the deposition and accumulation of amyloid in the walls of blood vessels
preventing the export of neurotoxic molecules through perivascular space (Weller, R. O. et al.,
2009). This pathology can also lead to reductions in capillary number, increases in microvascular
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tortuosity, and occlusions within these microvessels (Lee, J. et al., 2003; Roher, A. E. et al., 2003;
Thal, D. R. et al., 2009). Individuals exhibiting these changes show reductions in vascular
reactivity and hallmark signs of prolonged ischemia and inflammation (Lee, J. M. et al., 2003;
Roher, A. E. et al., 2003). Recently, the involvement of pericytes and MMPs have become a focal
point of study for the progression of CAA, as age-related pericyte loss has been considered to be
a potential contributor to the disease pathology (Schultz, N. et al., 2014). This could also mean
that prolonged microvascular ischemia leading the pericyte loss could present a novel means of
initiating CAA.
In our model of microvascular ischemia we were able to show pericyte specificity in
BBB breakdown during the progression of ischemic injury. This response is interesting because a

Figure 20. Histological depiction of photothrombotic stroke. (A) Neurons (blue), vasculature (green) and
pericytes (red) following 24 hr photothrombosis with (B) pericyte dysfunction in the peri-infarct region and
healthy pericytes further from the ischemic core (region of lost NeuN). (C) A burst pericyte somata on a
region of BBB damage.

79
disproportionate amount of vascular damage occurs in relation to relatively sparse pericyte
somata coverage of the microvascular (<8% coverage is related to > ~75% leakage). What we do
not know, is whether or not the cellular specificity seen in our studies are indicative of a cellular
response to microvascular ischemia in the previously mentioned diseases. We have some data
suggesting that pericytes are the locus of leakage in the peri-infarct region in stroke, but this data
is limited to histological examination (Figure 20) as our model simply attempted to replicate
capillary dysfunction in larger stroke models. We have also been able to show overlap between
pericytes and MMP activity with the occlusion of larger blood vessels, but the rapid nature of
BBB breakdown following this type of injury makes in vivo visualization of this phenomenon
difficult to capture beyond the very early time points (Figure 21). The initial data collected does,
however, suggest pericytes contribute to proteolytic responses to larger injuries. Additionally,
animal models of AD show upregulation of MMP 9 which is associated with the loss of pericytes
and further BBB degeneration (Halliday, M. R. et al., 2016; Lee, J. M. et al., 2003). This
proteolytic response seems to be a common feature of pericytes under ischemic or inflammatory
conditions.

4.3 Pericytes as a source of matrix metalloproteinase 9
As exploration of pericyte involvement in the pathogenesis of inflammatory and ischemic
injury has become more prevalent, proteolytic activity has become a common biochemical step in
pericyte response to injury. From traumatic brain injury (Østergaard, L. et al., 2014), to stroke
(Lui, S. et al., 2012), to neurodegeneration (Ostergaard, L. et al., 2016; Zlokovic, B. V., 2005),
and even diabetic retinopathy (Hammes, H. et al., 2002; Kowluru, R. et al., 2012), pericytes and
the gelatinases have been implicated. Many of the signaling mechanisms during the ischemic
cascade (mentioned previously) have been demonstrated in these disease states leading to the
nuclear localization of NF-κβ and resulting transcription of MMPs. In AD models, cyclophilin A
activation of NF-κβ is thought to play a role in MMP 9 transcription along with the signaling
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Figure 21. Proteolytic
activity localized to
pericyte somata following
the photothrombotic
occlusion of a penetrating
arteriole.

mechanisms common in these other disease (Bell, R. D. et al., 2012). The research here provides
a complementary finding in that MMP 9 upregulation during ischemia plays a critical role in
BBB degeneration following ischemic injury. An interesting element that has been difficult to
understand and probe is the temporal aspect of MMP 9 activation. The rapidly occurring MMP 9
activation elucidated in our research suggests that low levels of basal pro-MMP 9 may be able to
produce localized BBB damage that could provide a basis for understanding comorbidities of the
aforementioned diseases. It may also provide evidence that inflammatory insults may break the
homeostatic balance in MMP 9 regulation and provide a source of available pro-peptide, even at
low levels, for activation and subsequent vascular damage.
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As mentioned previously, activation of pro-MMP 9 can occur in the presence of activated
MMP 2. The association between MT1-MMP and MMP 2 controls the spatial function of
activated MMP 2, but could also control the spatial activation, and therefore function, of MMP 9
(i.e. activation following secretion). With the production of a very small injury (0.007 mm3) we
were able to show that MMP 9 activation could lead to BBB opening localized to the site of
pericytes. This dynamic response was not prevented with an MMP 2 inhibitor, suggesting an
alternative means of activation. When an inhibitor of nitric oxide synthase was presented, at high
enough concentrations, the localized pericyte leakage events were inhibited. This result suggests
the involvement of a rapid NO mediated mechanism of MMP 9 activation at the site of pericytes
(Figure 21). When considering the implications of the rapid and localized manner in which MMP
9 can be activated, it seems that diseases or genetic based modifications in this pathway could
increase susceptibility to neurodegenerative disease and stroke.

Figure 22. Summary of the proposed influence of ischemia resulting in elevated MMP activity at the location
of pericytes through both protein synthesis mediated (green) and protein synthesis independent processes
(red).

It should also be mentioned that a variety of cells in the CNS have been shown to express
MMPs under the experimental conditions we produced in our model of microvascular ischemia.
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Although we were able to show very nice overlap between pericyte somata and gelatinase activity
at locations of leakage, we cannot rule out the contribution of MMPs by other cells and
subsequent activation within the location of pericytes. It seems unlikely, however, that pericytes
are not contributing in some manner to the activation or production of MMP 9 during this
pathological process due to the fact that sparsely present pericyte somata represent loci for the
vast majority of sites of BBB degeneration.

4.4 Next steps
The production of this model, and the resulting demonstration of a pericyte-specific
response, has opened the door to numerous questions regarding the spatiotemporal dynamics of
cell-specific proteolytic responses to animal models of disease. Moving forward with this work it
would be important to understand the specific cellular contributors to nitric oxide and pro-MMP 9
during capillary ischemia across diseases with this type of pathophysiology. Although we have
demonstrated, and previously discussed, the colocalization between pericyte somata and
gelatinase activity, inducible genetic manipulations of these biochemical signaling molecules
would add an enormous amount of insight to our understanding of this pathway. It would also be
pertinent to understand basal reservoirs of available pro-MMP 9. In the data presented here we
have shown a protein synthesis independent effect of MMP activation. This would suggest the
possibility that pathological activation of readily available MMP 9 can occur. This could mean
that low levels of basal pro-MMP 9 could be substantial enough to degrade portions of the BBB
during ischemia resulting in vascular leakage. Although we know the half-life of tissue inhibitors
of metalloproteinases (TIMPs) are very short (tens of minutes) the relative bioavailability of
MMPs is not well characterized. This is another area of exploration that would shed some light on
the rapid activation of MMPs seen in our experiments. Finally, exploring the progression of
capillary occlusions during disease states could put our model into the appropriate context. This is
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an important step as we have provided a means of understanding a component of variety of
diseases, but the larger context is still in question.
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APPENDIX 1
Photothrombotic Induction of Capillary Ischemia in the
Mouse Cortex during in vivo Two-Photon Imaging

Robert G. Underly and Andy Y. Shih

Photothrombosis of blood vessels refers to the activation of a circulating photosensitive
dye with a green light to induce clotting in vivo (Watson et al., 1985). Previous studies have
described how a focused green laser could be used to noninvasively occlude pial arterioles and
venules at the brain surface (Schaffer et al., 2006; Nishimura et al., 2007; Shih et al., 2013). Here
we show that small regions of the capillary bed can similarly be occluded to study the ischemic
response within the capillary system of the mouse cerebral cortex. The advantage of this approach
is that the ischemic zone is restricted to a diameter of approximately 150-250 μm. This permits
higher quality two-photon imaging of degenerative processes that would be otherwise difficult to
visualize with models of large-scale stroke, due to excessive photon scattering. A consequence of
capillary occlusion is leakage of the blood-brain barrier (BBB). Here, through the use of twophoton imaging data sets, we show how to quantify capillary leakage by determining the spatial
extent and localization of intravenous dye extravasation.

Numerous animal models exist to induce ischemia on a large scale via occlusion major
cerebral arteries (Carmichael, 2005). However, there are some aspects of stroke that are not
accessible to in vivo two-photon imaging. In regions experiencing more severe ischemia, cells swell
due to ionic imbalance, and this edematous process contributes to increased light scattering, greatly
reducing the quality and depth of in vivo two-photon imaging. A smaller zone of ischemia would
reduce photon scattering, and still allow neurovascular changes associated with ischemia to be more
clearly visualized over time in vivo.
We recently showed that spatially restricted regions of ischemia could be generated by focused
photothrombotic irradiation of the cortical capillary bed (Underly et al., 2017). Capillary occlusions
were highly reproducible, could be targeted to specific locations, and initiated at precise times
through a cranial imaging window. The resulting ischemic zone occupied less than 1% of the area
accessible through a typically cranial window (Figures 1D and 1E), allowing multiple strokes to be
examined in one window.
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Here, we describe the steps involved in inducing photothrombotic occlusion in a small
region of the capillary bed during in vivo two-photon imaging. We build upon a previous protocol
in which individual cortical penetrating arterioles were occluded, rather than capillaries (Taylor
and Shih, 2013). We also demonstrate the analysis of BBB leakage produced as a consequence of
capillary occlusion using Imaris, a 3-D visualization software.

Materials and Reagents

1.

Filter paper (GE Healthcare, catalog number: 1001-0155)

2.

Cotton swabs (Fisher Scientific, catalog number: 23-400-119)

3.

Cover glass (thickness: No. 0) (Thomas Scientific, catalog number: 6661B40)

4.

0.3 ml insulin syringes (BD, catalog number: 328438)

5.

Petri dish

6.

An adult mouse of any common laboratory strain, ~25 to 35 g in weight

7.

Isoflurane (Patterson Veterinary Supply, catalog number: 07-806-3204)

8.

Phosphate buffered saline (PBS) (Sigma-Aldrich, catalog number: P4417-50TAB)

9.

Agarose type 3-A (Sigma-Aldrich, catalog number: A9793)

10. Fluorescein-dextran (2 MDa; 5% w/v in saline) (Sigma-Aldrich, catalog number: FD2000S)
11. Rose Bengal (1.25% w/v in saline) (Sigma-Aldrich, catalog number: 330000-1G)
12. Buprenorphine hydrochloride (Buprenex®) (Patterson Veterinary Supply, catalog number: 07-8919756)
13. Sodium chloride (NaCl) (Sigma-Aldrich, catalog number: S7653-1KG)
14. Potassium chloride (KCl) (Sigma-Aldrich, catalog number: P9333-500G)
15. Calcium chloride (CaCl2) (Sigma-Aldrich, catalog number: C1016-100G)
16. Magnesium chloride (MgCl2) (Sigma-Aldrich, catalog number: M8266-100G)
17. Glucose (Sigma-Aldrich, catalog number: G8270)
18. HEPES (Sigma-Aldrich, catalog number: H7006)
19. Artificial cerebral spinal fluid (ACSF) (see Recipes)

Equipment

1.

Heating pad with feedback regulation (FHC, catalog number: 40-90-2-07)

2.

Heating pad control system (FHC, catalog number: 40-90-5D-02)

3.

Rectal Thermistor Probe (FHC, catalog number: 40-90-8)

4.

Isoflurane vaporizer (Datex-Ohmeda, model: IsoTec4)

5.

Induction chamber (VetEquip, catalog number: 941444)
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6.

Dental drill (Osada, model: EXL-M40)

7.

Auxiliary equipment for two-photon microscope (Sutter Moveable Objective System [Taylor and
Shih, 2013])
a.

Objective lens 4x, 0.16 NA (Olympus, model: UPLSAPO)

b.

Objective lens 20x, 1.0 NA, Water immersion (Olympus, model: XLUMPlanFI)

c.

Green laser 532 nm (Beta Electronics, model: MGM20). Details for how the green laser line is
directed into the Sutter MOM imaging beam path was described in a separate protocol (Taylor
and Shih, 2013)

8.

Computer specifications (for Imaris)
a.

16 GB RAM

b.

3.3 GHz CPU

c.

AMD Radeon RX 480 4GB or better

d.

1280 x 1024 Resolution Monitor

Software

1.

2.

Imaris (Bitplane)
a.

Imaris 7.6 (or current)

b.

Imaris Batch Module

Fiji Software (https://imagej.net/Fiji/Downloads)

Procedure

A. Cranial windows

In order to perform photothrombotic occlusion of capillaries, a cranial imaging window must
be generated in the mouse skull. Both thinned skull windows (Drew et al., 2010; Yang et al.,
2010) and windows involving full removal of skull can be used (Holtmaat et al., 2009).
Occlusions can also be performed through windows that are acute (< 24 h) or chronic. Images
shown in this protocol used polished and reinforced thinned-skull windows (PoRTs), and a
video and detailed written procedure for this window type is available (Shih et al., 2012a and
2012b).

B. Two-photon microscope and laser for photothrombosis

Our system passes a green laser beam through to the imaging objective via the two-photon
imaging beam path (Figures 1A and 1B). The microscope we use is a Sutter Moveable
Objective Microscope, and details for how to introduce a green laser has been described
previously (Taylor and Shih, 2013). The green laser greatly under-fills the back aperture of the
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Figure 1. Photothrombotic occlusion of capillaries in mouse cortex. A. Schematic
illustrating two-photon imaging laser and B. photothrombotic green laser beam paths in a
typical two-photon imaging microscopy. C. The objective brings the green laser to a focus in
upper layers of cortex allowing for photothrombotic irradiation of capillaries. D. Wide-field
vascular map of the imaging area contained within the PoRTS window, obtained by montaging
several maximally z-projected images collected using a 4x objective. E. Magnified region
within the window, visualized with a 20x objective (projected over 100 µm of depth, beginning
~10 µm below the pial surface), showing ischemic damage to capillaries over 24 h.
20x objective (Olympus; XLUMPlanFI), yielding a fixed laser focus with ~20-40 μm diameter
at the imaging plane. The power of the green laser is ~1 mW at the sample. Prior to initiating
photothrombotic occlusion, the location of the green laser focus should be determined. To do
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this, we place a small piece of filter paper in a Petri dish, apply 25 µl of fluorescein-dextran
onto the filter paper and cover with a cover glass. The filter paper is imaged using the 20x
objective, and then irradiated with the green laser. The green laser photobleaches the
fluorescent dye at its focus, providing a target location relative to the imaging field (Figures
2A and 2B). This is also described in-depth in a previous protocol (Taylor and Shih, 2013).
The filter set we use to detect fluorescein-dextran emission is 525/70m-2P (Chroma Corp).

Figure 2. Green laser focusing for targeted photothrombosis. A. FITC-Dextran on filter
paper prior to irradiation with green laser; B. Photobleached region of filter paper
following irradiation with green laser light revealing the laser focus.

C. Targeted photothrombotic occlusion
1.

Anesthetize the mouse and affix the animal’s head to a stable imaging apparatus under the twophoton microscope. For anesthesia, the data shown here is collected from a C57BL/6 mouse under
0.75 to 1.5% isoflurane supplied in medical air. However, other types of anesthesia can also be used.
Typically, a custom machined aluminum flange is attached to the head using dental cement during
a pre-surgical procedure. Later, the metal flange can be secured to a custom holder using screws.
There are many variations of head fixation that are compatible to this protocol. See methods in Shih
et al. (2012a) for one method for head fixation of mice.

2.

Administer 25 µl of 5% w/v fluorescein-dextran (2 MDa) into the infraorbital vein. Using a 0.3 ml
insulin syringe, carefully inset the needle tip 3 mm into the corner of the eye closest to the animal’s
midline. To ensure that the needle does not penetrate too deeply, place a mark on the needle 3 mm
from the tip using a black marker. The needle should go behind the eye, slightly pushing the eye
laterally. Inject the contents of the syringe over a period of 20 sec. None of the solution should
accumulate outside the eye, when correctly administered. Withdraw the syringe and carefully clean
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the eye with a moistened cotton swab. Ophthalmic ointment should then be applied to both eyes to
avoid desiccation. A video for this procedure is also available (Shih et al., 2012b). This procedure
should be done under anesthesia, and with care to avoid damage to the eye. The vasculature should
be clearly visible with two-photon imaging immediately after injection. Too deep an insertion of the
needle will result in fluorescein-dextran within the cranium and increased subdural fluorescence
during two-photon imaging.
3.

Starting at a low magnification with the 4x objective, obtain z-stacks of the vasculature over the
entire cortical area accessible through the cranial window. These images, when montaged, provide
a map of the cortical vasculature for navigation at higher magnification (Figure 1D).

4.

Change to the 20x objective and focus on the larger vessels at the pial surface. Use the map collected
at lower magnification to determine your location within the imaging window.

5.

Locate a region of capillaries without larger vessels overlying them (Figure 1E). When finding a
capillary location of interest, target a region at least 20 µm away from larger penetrating vessels,
which may lead to larger strokes if inadvertently occluded.

6.

Place the target of the green laser over the region of the capillary bed that is to be irradiated (Figures
1D and 1E; white dot).

7.

Inject 25-50 µl of 1.25% Rose Bengal into the infraorbital vein, using the same method describe
above for fluorescein-dextran.
IMPORTANT: Check to be sure that the field of view and green laser focus has not shifted prior to
beginning laser irradiation.

8.

Initiate photothrombosis by turning on the green laser light (Figure 1B) (1 mW at the sample) and
allowing irradiation for 25 sec.
IMPORTANT: The Rose Bengal dye will only remain in the blood stream for ~5-10 min, with rapid
removal from the blood plasma over this period. Thus, it is important to perform irradiation as
quickly as possible after administering Rose Bengal.

D. Imaging the evolution of capillary ischemia

One can expect to observe complete cessation of blood flow in ~10 capillary segments within
a 211 x 211 x 150 µm cube of tissue immediately after the 25 sec irradiation (Figure 3A; yellow
arrowheads). A capillary segment is defined as a length of capillary between branch-points.
The integrity of the capillary wall is typically maintained in for the first 0.5-1 h after which
localized sites of dye leakage begin to appear from non-flowing capillaries (Figure 3A; white
arrows). The number of these leakage sites increases gradually over a period of 3 h. For each
imaging time-point, we collect image z-stacks of the irradiated region. While our studies have
characterized changes occurring in the first 3 h post-occlusion (Underly et al., 2017), the
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precise experimental time-line and imaging interval can be adapted based on the experimental
question.

Figure 3. In vivo observation and post-hoc quantification of capillary leakage. A. In vivo
tracking of capillary leakage over 3 h following photothrombotic irradiation of cortical
capillaries; B. Two-dimensional (left) and 3-dimensional (right) representation of capillaries
before irradiation. Sixteen ROIs (purple) are strung along a capillary segment in the 3dimensional panel, with ROI 8 positioned at the central point of leakage. C. The same vessels
are shown 1 h after irradiation, when fluorescein-dextran leakage is evident. D. Graph of
fluorescein-dextran volumes pre (dotted line) and post (solid line) irradiation, corresponding to
the capillary leakage site. The post-irradiation dye volume trace for data of panel C is shown as
solid red line.

E. Image processing

Imaris supports numerous imaging formats, but Fiji software can be used to convert formats
not compatible with Imaris to .tif files. Ensure that the pixel/micron ratios for x-y and z planes
are correctly entered into Imaris. The ratios can be modified in Image Properties within the
Imaris software. It is also important to consider your file names as Imaris will combine similar
file names not separated into different folders.
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1.

Begin by identifying the initial regions of dye leakage by utilizing the two-dimensional .tif stacks
in Fiji. These are regions in which the intravascular dye has begun to expand beyond the initial (preimage) border of the blood vessels, and are associated with a region of high intensity fluorescence
(Figure 3A; white arrows).

2.

Using Imaris, open the image stacks containing the fluorescein channel, captured during or after dye
leakage has begun.

3.

With an image rendered in 3-dimensions in Imaris, string regions of interest (ROIs) along the
vasculature where leakage is occurring (Figures 3B and 3C; purple, right column).
a.

These ROIs are created by using the ‘Surface’ feature in Imaris and selecting the ‘region of
interest’ option.

b.

Start by placing an initial region identified at the site of leakage. Then string ROIs outward
from this central point, without overlap, to sample surrounding regions of the capillary segment.
These ROIs should be appropriately sized so that the depth of the ROI is never completely filled
to avoid a volume ceiling effect which would prevent finding the region of peak dye
extravasation.

Data analysis

With ROIs volumetrically rendered (the concluding step in Surface creation) a graphical
representation of the volumes can be produced. This can be done by graphing the dye leakage
volumes within each ROI (found in the ‘statistics tab’ of Imaris). By having several ROIs strung
along the capillary, areas with a significant increase in leakage can be differentiated by showing
a significant change in volume between ROIs from images prior to, and following, capillary
occlusion (Figure 3D). This difference can be found by performing t-tests comparing each of
the corresponding ROIs (ROI 1 pre vs. ROI 1 post, etc.). An ANOVA may be necessary instead
of a t-test if the number of groups or times used during experimentation fit the criteria for an
ANOVA.

Notes

In regard to the capillary occlusions and dye leakage, there is a lot of variability in the volume
of dye depending on the time of sampling. It is important to image at time points (every 15 min
or more) frequent enough to capture the formation of the event.

Recipes
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1.

Fluorescein-dextran
5% (w/v) in sterile PBS
Preloaded as aliquots in 0.3 ml insulin syringes
Stored at -20 °C

2.

Rose Bengal
1.25% solution (w/v) in sterile PBS
Preloaded as aliquots in 0.3 ml insulin syringes
Stored at -20 °C

3.

Artificial cerebral spinal fluid (ACSF)
125 mM NaCl
5 mM KCl
10 mM glucose
3.1 mM CaCl2
1.3 mM MgCl2
10 mM HEPES (pH 7.4)
Maintain at 4 °C
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